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ABBREVIATIONS  
µg microgram 
µL microliter 
µM micromolar 
µm micrometer 
ABCB1 ATP-binding cassette transporter B1 
ADME absorption, distribution, metabolism and elimination 
ADP adenosine-5`-diphosphate 
AM acetoxymethyl ester 
ATP adenosine-5`-triphosphate 
BV2 immortalized mouse (strain: C57BL/6) microglia cells 
Bz-ATP 2`, 3`-O-(4-benzoylbenzoyl)-adenosin-5`triphosphate 
cDNA complementary deoxyribonucleic acid 
CO2 carbon dioxide 
Da Dalton 
DDI drug-drug interaction 
DILI drug-induced liver injury 
DMEM Dulbecco`s modified Eagle medium 
DMPK Drug Metabolism and Pharmacokinetics 
DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
EBM endothelial basal medium 
EC50 half maximal effective concentration 
EDTA ethylenediaminetetraacetic acid (disodium salt) 
EGM endothelial growth medium 
FADH flavin adenine dinucleotide (reduced form) 
FBS fetal bovine serum  
g gravitation constant 
GSH -L-glutamyl-L-cysteinylglycine (or: glutathione) 
h hour 
HBSS Hanks` balanced salt solution 
HCl hydrochloric acid 
HEK293 human embryonic kidney cell line 
HEK-hP2X7 human P2X7 overexpressing HEK293 cells 
Hepes 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HepG2 human hepatocarcinoma-derived cell line 
HPLC high performance liquid chromatography 
i.e.  id est 
IC50 half maximal inhibitory concentration 
IgG-HRP immunoglobulin G-coupled with horseradish peroxidase 
IL-1b or IL-1 interleukin-1 
Abbreviations 
2 
IU international unit 
k kilo 
KM Michaelis-Menten constant 
LC-MS liquid chromatography coupled to mass spectrometry 
LLC-PK1 porcine kidney epithelial cell line 
L-MDR1 porcine kidney epithelial cell line transfected with human mdr1 gene 
M molar 
m/z mass over charge ratio 
MDR1 multi drug resistance gene-1 
MDR1-G1 mouse monoclonal antibody raised against amino acids 1040-1208 of 
human mdr1 protein 
MEM modified Eagle medium 
mg milligram 
min minute 
mL millilitre 
mM millimolar 
MTT 3-(4, 5-dimethyl-2-thiazolyl)-2, 5-diphenyl-2H-tetrazolium bromide 
NADH nicotinamide adenine dinucelotide (reduced form)  
NAPQI N-acetyl-p-benzoquinone imine 
NC nitrocellulose 
nM nanomolar 
nm nanometer 
P2X7 purinergic ligand gated ion channel  
PBS phosphate buffered saline 
P-gp permeability glycoprotein 
pH negative logarithm of the hydrogen ion concentration 
RNA ribonucleic acid 
ROS reactive oxygen species 
rpm rotations per minute 
s second 
SDS-PAGE sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
SEM standard error of the mean 
UK United Kingdom 
US United States of America 
UV ultraviolet 
V volt 
v/v volume/volume 
Vmax maximum rate 
wt wild type 
w/v weight/volume 
YoPro1 4-[(3-methyl-2(3H)-benzoxazolylidene)methyl]-1-[3-
(trimethylammonio)propyl]-, diiodide 
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1 INTRODUCTION 
1.1 General 
This dissertation yields a means to support drug research based on the monitoring of cellular 
energy pathways. Moreover, the newly achieved approach presented here resolves key 
mechanistic issues from various sections of drug discovery and development, thus 
representing a beneficial and supportive tool for the pharmaceutical industry. 
 
1.2 Drug discovery and development  
The basic mission of the pharmaceutical research industry is to understand disease and to 
provide safe and effective drugs for patients.  
Drug discovery and development are two distinguished processes that contribute to the drug 
research pipeline. The whole story of drug research starts with the drug discovery process. 
Once a lead compound is identified, it enters the drug development process (Figure 1). 
 
Figure 1. Drug discovery and development is a long process that starts with the selection of a disease and the 
pharmaceutical target identification. Following a multitude of processes in drug discovery, the compound 
enters preclinical trials and subsequently the clinical phases (Phase I, II, III) before it can be launched on the 
market. 
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1.2.1 Drug discovery 
The initial issues in drug discovery involve choosing a disease, selecting a disease-specific 
target, and finding a suitable assay to determine the activity of molecules with respect to the 
selected target. In the past, most drugs were discovered by identifying ingredients from 
traditional remedies or plants. Today's drug discovery is supported by enormous knowledge 
of the mechanisms of diseases, and how these diseases are controlled. With this information 
and a deeper insight, the scientist can search for molecules that modulate targets in a 
selective manner. Selectivity can play a pivotal role in the development of fewer side effects, 
but has also proved beneficial for new and unexpected indications for drugs (1). In any case, 
the drug discovery track is difficult and similar to the proverbial search for the needle in a 
haystack. However, once a molecule is successful in the screening process, the next step in 
drug discovery is the identification of a lead compound, which is a molecule that exhibit 
activity towards the target, but is not yet good enough to be the drug itself. Combinatorial 
chemistry (involves rapid synthesis and computer simulations) provides a large number of 
slightly modified molecules for compound lead identification and optimisation. These 
synthesised analogues are analysed in large screening studies to show their potential activity 
with respect to the target. Simultaneously the first safety experiments (cytotoxicity assays, 
cytochrome P450 inhibition, covalent binding to cell proteins, metabolic stability, plasma 
protein binding) were investigated to assess the potential risk of the compounds and to 
support lead compound optimisation. Once a pharmacophore is identified, the optimisation 
of the molecule can focus more on the feature of the pharmacophore responsible for the 
activity towards the target. Irrespective of all the advantages of the new technologies, drug 
discovery is still a long, expensive, and inefficient process (Figure 2) requiring more and more 
support technologies to yield a more economical and successful process (2). 
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Figure 2. Stages of the drug development process. This chart represents the attrition rate of compounds as 
they travel through the drug development process over time. Starting with 10`000 candidates, only one will 
finally make it to market (from: www.PhRMA.org, January 2012, Washington, US). 
1.2.2 Drug development 
Drug discovery and development are more of interdependent than rigorously separated 
processes. Preliminary tests in the developmental stage, before lead compound selection, 
can help eliminate poor drug candidates in the early process and thereby save limited 
resources. However, once a lead compound has been selected in the drug discovery process, 
the new drug candidate enters the drug development process. Drug development consists of 
two different disciplines: preclinical research and clinical trials (Figure 1). Prior to "first in 
man", the preclinical department provides required data (e.g. toxicity, pharmacokinetics and 
-dynamics, metabolism, enzyme induction, drug transport, etc.) for the new drug candidate 
to the regulatory authorities for the clinical Phase I trial. In addition to the safety profile of 
the drug, the preclinical department recommends the first human dose for the clinical trial, 
estimated from several toxicology, efficacy, and supporting experiments. To follow 
regulatory requirements, a number of tests are available to determine the toxicity of the 
new drug candidate before it enters the first clinical trial in humans. Section 1.5 - Toxicology 
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in drug research – depicts in more detail the requirements of toxicity studies in drug 
research. Briefly, many cell-based in vitro and in vivo experiments are performed to examine 
the safety of the new drug candidate and the collection of all data is required for the next 
steps. Finally, all data gathered from the studies are collected in an Investigational New Drug 
application (IND) and then submitted to the regulatory authorities for approval of the clinical 
trials. It is worth mentioning that the costs to bring a new drug to market are above 
500 million dollars (3, 4), the process taking an average of 10 to 15 years, with a success rate 
of only 0.01%. This means that, of every 10`000 compounds that enter the research and 
development pipeline, ultimately only one drug receives approval (Figure 2) (5). Taking this 
in perspective, to say the least the implementation of new technologies that can support the 
drug research process in an economical manner will be appreciated. 
 
1.3 Drug interactions  
The terms drug interactions refers to circumstances in which the efficacy of a drug is altered, 
be it an increased or decreased thereof, or a completely different effect occurs. Several 
kinds of drug interactions are known; i.e. the interaction of two administered drugs (drug-
drug interactions, DDI), or the interaction of an administered drug with ingredients in food. 
Epidemiology shows that, among adults older than 55, at least 4% take medication and 
supplements, putting them at risk of DDI (6-8). That is why DDIs remain a decisive issue in 
drug research. The earlier the DDI can be detected, the greater the probability that this 
deleterious effect can be changed by the design of the molecule. In the pipeline of drug 
research, several mechanistic approaches are implemented to assess the DDIs potential of a 
drug candidate (e.g. enzyme inhibition and induction, transport substrate and inhibition 
identification, etc.). Drug interaction has a crucial influence on the pharmacokinetic and 
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pharmacodynamic of drugs. Regarding the pharmacodynamic, the effect of the drug on a 
disease can be potentiated or simply lost. The pharmacokinetic of a drug can be subdivided 
into absorption, distribution, metabolism, and excretion (ADME) processes of the drug 
molecule in the body. This ADME process can be significant altered by a DDI, e.g. by 
inhibition or induction of metabolising enzymes or by inhibition of transport proteins (e.g. 
ABC-transporters, solute carrier, etc.) (9). Drug transporters mediate the uptake or efflux of 
a broad variety of endogenous compounds, metabolites, or drugs (10, 11). The transporters 
are well distributed in the body and are found highly expressed in tissues were they playing 
pivotal roles. P-glycoprotein (P-gp, ABCB1), the most famous member, is found at high levels 
at the blood-brain barrier endothelia, protecting the brain from brain-critical substances, but 
also at the level of the small intestine, where it can deny drug entry into the systemic 
circulation. Drug-drug interactions with transporters occur when translocation of a drug is 
disturbed by a second drug. This alteration by a second drug can function via inhibition or 
induction (12-14). In recent years, scores of DDI studies with drug transporters have been 
investigated and concern with molecules interacting with drug transporters has become ever 
more important (15-21). It is great aspiration in drug research to design drugs that show no 
undesirable interactions with drug transporters. The importance of the function of drug 
efflux pumps is well established with the neurotoxic pesticide ivermectin. Ivermectin itself is 
a substrate for P-gp and consequently is not able to cross the blood-brain barrier and enter 
the brain, as shown in Figure 3. In cases where ivermectin is co-administrated with a drug 
that has P-gp inhibition potential, ivermectin can cross the blood-brain barrier and enter the 
brain with fatal neurotoxic consequences (22). This observation was confirmed in mouse 
models lacking the expression of P-gp (mdr1a-/b-) and resulted in markedly elevated brain 
levels of ivermectin (23). Overall, ABC-transporters serve as protective shields by preventing 
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uptake or facilitating clearance of toxic substances. A guide on drug-interaction studies was 
provided by the regulatory authorities to cover the most frequent and known DDIs (24). 
Existing techniques are used regularly in drug research, but often come up against the limits 
of their potentials in the prediction of DDIs. For all of the above reasons, I decided to test the 
possibility of real-time, label-free substrate identification of the drug efflux pump, P-gp. 
 
Figure 3. Putative localisation of drug efflux proteins on the plasma membrane of brain capillary endothelial 
cells that form the blood–brain barrier. The proposed direction of transport is indicated by black arrows. 
Only efflux transporters that are localised on the apical (luminal) side of the brain capillary endothelium 
would be in a position to restrict brain uptake of xenobiotics. (A) Indicates the protective function of 
P-glycoprotein (Pgp) at the level of the blood-brain barrier using ivermectin as an example of a P-gp 
substrate. Ivermectin cannot enter the brain, owing to the active efflux of P-gp from the brain capillary cell. 
(B) Co-administration of a P-gp inhibitor or a competing drug can block the protective function and 
ivermectin can penetrate the brain capillary cells and thus enter the brain, with dramatic neurotoxic 
consequences. It should be noted that this figure represents only a simplified scheme of drug-efflux 
transporter distribution at the blood-brain barrier. There are various other transporters localised in brain 
capillary endothelial cells (25), which are not illustrated here because their potential role, if any, in drug 
efflux is not clear. In consideration of the fact that ivermectin penetration is on the basolateral side, 
involvement of MRP1 (multi-drug resistance protein-1) as well as passive diffusion was analysed (26). 
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1.3.1 ABC-Transporters and their famous member: P-glycoprotein (ABCB1) 
ATP-binding cassette (ABC) transporters are one of the largest families of multidomain 
integral membrane proteins that use ATP hydrolysis energy to translocate molecules across 
cell membranes. They are found in all species including man (27). These efflux pumps 
recognise a wide range of chemically diverse endogenous and exogenous compounds and 
act as gatekeepers, contributing to cell defence (28, 29). They are involved in biomedical 
phenomena such as the multidrug-resistance of cancer cells or the poor bioavailability of 
drugs (30, 31). One of the best-characterised ABC-transporters is P-gp, the gene product of 
the human multi-drug resistance (MDR1) gene and the first member of subfamily B of the 
ABC-transporters (ABCB1). P-gp is highly expressed in human tissues that have a protective 
function and is found on the luminal surface of cell barriers, including the kidney proximal 
tubule, small intestine, colon, testis, adrenal cortex, and the blood-brain barrier (17). The 
expression pattern of P-gp suggests a protective function of P-gp towards potentially toxic 
xenobiotics. P-gp is a 170 kDa protein consisting of two homologous drug-binding 
transmembrane domains (32) and a cytosolic nucleotide-binding domain with ATPase 
activity (33). P-gp recognises and couples its substrates in the cytosolic membrane leaflet 
(32) and translocates them from the cytosolic membrane leaflet out of the cell or to the 
outer membrane leaflet, which prevents substrate uptake into the cytosol (34). Transporting 
the drug consumes two ATP molecules; one ATP is required to induce the drug-releasing 
conformation, the second to reset P-gp to the drug-binding conformation (35, 36). The rate 
of ATP hydrolysis in the transport process correlates linearly with the rate of effective 
transport (37, 38) and can therefore used to monitor P-gp activity.  
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1.3.2 Identification of P-glycoprotein substrates: A challenge  
P-gp has a broad substrate range and modulates the pharmacokinetics of many, chemically 
unrelated drugs (39). As a consequence, efficient screening methods are needed to identify 
substrates or inhibitors of P-gp during the drug discovery and development process (40). 
High-throughput fluorescent assays exist to identify P-gp modulators, including the 
rhodamine123- (41) or the calcein-AM (42) assay. However, identification of substrates of 
P-gp remains a challenge: predictive cellular assays such as the transcellular transport assay 
(43) or any in vivo experimentation relies on sensitive, compound-specific, and expensive 
analytical procedures such as the use of radiolabeled test compounds or quantitative mass 
spectroscopy. In contrast, generic biochemical assays such as the ATPase release assay (44) 
make use of membrane preparations of P-gp-expressing cells. However, these assays are not 
necessarily representative of the in vivo situation, because membrane integrity is disturbed 
and the orientation of P-gp binding sites towards the intracellular or extracellular space is 
lost during the preparation of cell homogenates. Schwab et al. (2003) showed that the 
assays mentioned above and generally used in drug development demonstrate limitations in 
terms of the reliable identification of P-gp substrates; ten of 28 P-gp substrates were not 
identified by analysis as substrates in either one or more of these assays (40). Because it is 
well understood, that P-gp requires energy in the form of ATP for the translocation of drugs 
out of the cell (Figure 4), this consumed ATP must be regenerated intracellularly, which 
results in a higher consumption of oxygen and a release of acidic metabolic products. A 
system that can monitor such alterations should be able to identify P-gp modulators in an 
effective and elegant way. 
Introduction 
11 
 
Figure 4. P-glycoprotein binds its substrates in the cytosolic leaflet of the plasma membrane and translocates 
them into the outer membrane leaflet or into the extracellular compartment. The active transport utilises 
ATP for translocation (PI: phosphate). 
1.4 Target characterisation in drug discovery 
Finding new medications based on knowledge of biological targets require an intensive 
ligand design process (45). The number of new entities approved by the Food and Drug 
Administration (FDA) in the last few years remains stable, with only 18 to 26 newly approved 
drugs per year (46). The reasons for the stagnated number are multifactorial (47, 48). 
However, it is recognised that a crucial step in drug discovery is the initial identification of a 
disease relevant target and target characterisation, and this seems to be one of the main 
bottlenecks (49-51). In particular, drug discovery repeatedly struggles with the limitations 
associated with the existing cell-based in vitro models for the characterisation of new 
targets. To circumvent such limitations in drug discovery, implementation of new 
technologies plays a pivotal role in successful characterisation of new disease relevant 
targets. Therefore, one of the sub-projects of this thesis was to characterise the purinergic 
P2X7 receptor. 
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1.4.1  Purinergic P2X7 receptor mediates metabolic alterations 
Ubiquitous adenosine triphosphate (ATP) influences innumerable cellular metabolic 
mechanisms (52, 53), provides energy for transporters that translocate molecules against 
concentration gradients, facilitates muscle contraction, and drives protein synthesis and 
degradation. It thereby underpins vital chemical (e.g. oxidative phosphorylation) (52), 
mechanical (e.g. motor proteins) (53, 54) and biochemical (e.g. glycolysis) processes in the 
cell (55, 56). Intracellular concentrations of ATP range from 1.0 to 10 mM (57), while 
extracellular ATP concentrations are typically very low under physiological conditions, being 
strictly regulated by the presence of ATPases (58). There are, however, conditions under 
which local extracellular ATP concentrations do reach high levels (58, 59). For example, ATP 
has been reported to be released at the synapses of neurons, where it acts as a 
neurotransmitter (60, 61). In addition, intracellular ATP is released into the extracellular 
environment in cases of cell destruction, necrosis, or hypoxia (62). In such cases, high 
extracellular ATP levels trigger immune system responses that lead to pro-inflammatory 
states and immune modulation of macrophages/monocytes, lymphocytes, mast cells and 
endothelial cells (63-65), in addition to initiating cell death in leukocytes and endothelial 
cells (66-68). These effects are thought to be induced, in part, by the purinergic receptor 
P2X7, which is activated by ATP only at concentrations above 500 µM (69, 70). This 
concentration is more than ten times higher than that required for ATP to activate other P2X 
or P2Y receptors (71, 72). Activation of the P2X7 receptor initiates a series of cellular 
responses that include depolarisation, secondary messenger activation of phospholipase C, 
and a rise in intracellular Ca2+ concentrations that stimulates caspase-1, cytokine release, 
and activation of p38 mitogen-activated protein kinase (73, 74). Sustained exposure 
(> 1 min) to ATP highlights the unique ability of the P2X7 receptor to form a large, non-
Introduction 
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selective pore (Figure 5) (75). The opening of the pore, which is permeable to molecules up 
to a molecular mass of 900 Daltons, results in complete depolarisation of the membrane 
potential (ion flux), cell swelling, and finally cell death (76-78). Interestingly, the activation of 
caspase-1 and mitogen-activated protein kinase pathways has been linked to P2X7 pore 
formation (79, 80). Moreover, pore formation has also been proposed as regulating 
physiological processes such as cell fusion and phagocytosis (81, 82). However, little is 
known to date of how extracellular ATP influences the regulation of metabolic pathways in a 
cell, and whether this occurs via the P2X7 receptor.  
 
Figure 5. Function and signalling pathways of the P2X7 receptor. (A) The P2X7 receptor is a homomeric cation 
channel. Each of the three subunits possesses two transmembrane domains (TM1 and TM2) (83), an 
extracellular loop with an ATP binding site and intracellular carboxyl (COO-) and amino termini (NH3
+). (B) 
Brief (< 10 s) activation of P2X7 with high concentrations of ATP (> 100 µM) lead to rapid, reversible channel 
opening with ion flux, followed by depolarisation (73). Acute receptor activation also initiates second 
messenger processes, resulting in phospholipase D (PLD) and caspase-1 activation. (C) Sustained activation of 
P2X7 receptor (> 1 min) induce large pore formation (> 4 nm), which triggers the enhanced influx of cations 
and molecules up to 900 Da (75). The rise of intracellular calcium and efflux of potassium activates the 
caspase-1 pathway and thus a conversion of pro-IL-1b (pro-interleukin-1) into IL-1b (interleukin-1) and 
release from the cell. Stimulation of the P2X7 receptor also leads to an activation of p38 mitogen-activated 
protein kinase (MAPK) (74). Prolonged activation of the P2X7 receptor leads to complete depolarisation of 
the membrane potential (ion flux), cell swelling, and finally cell death (76, 78, 84). 
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1.5 Toxicology in drug research 
Findings from human graves indicate the use of therapeutic agents as early as the Neolithic 
age and with the poor knowledge of the used agents, it was indeed a risqué to ingest 
substances that were potentially poisonous. A chemical entity itself does not constitute a 
poison; the entity must achieve a sufficiently `high` dose, which was attempted by 
Paracelsus as early as the sixteenth century. As depicted in the ratio of the median lethal 
dose (LD50) to the median effective dose (ED50), the therapeutic index has to be assessed 
very carefully. The goal of the pharmaceutical industry is obviously to develop safe drugs 
with high efficacy in therapy, which can narrow down the therapeutic index and has to 
assess carefully. 
Before entering the development process, drug candidates have first to be screened in 
different in vitro assays (i.e. biochemical and cellular assays), and the chemical structure of a 
potential drug optimised. Subsequently the most promising development candidates are 
investigated in more complex in vitro assays and pharmacological in vivo models. The latter 
consist mainly of rodents and possibly non-rodents. These in vivo models are concomitantly 
used to assess plasma concentration profiles and possible adverse effects. Compounds for 
development are selected based on the before mentioned battery of assays. These 
compounds are subsequently assessed in toxicology and safety pharmacology studies in 
order to enable "entry into man" (clinical Phase I) of the preclinical candidate. Non-clinical 
safety studies to conduct human clinical trials and to obtain marketing authorisation for 
pharmaceuticals are described in the ICH (International Conference on Harmonisation) 
M3 guideline (European Medicine Agency©, Canary Wharf, London, UK). Toxicology 
assessment consists of in vitro and in vivo studies covering genotoxicology/carcinogenicity, 
general (or repeated) toxicology, reproduction toxicology and safety pharmacology. The 
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read-out from the toxicology studies can indicate adverse effects, which will require 
additional experiments for the elucidation of the observed effects. Briefly, the 
genotoxicology studies consider the gene mutation potential of a drug and, in general, 
support all single dose clinical development trials. To support the multiple dose trials, an 
additional assessment capable of detecting chromosomal damage in the mammalian system 
should be completed. Carcinogenicity studies are commonly relevant for marketing. General 
toxicology studies, which are required, consist of repeated drug application to two 
mammalian species (one non-rodent) for several weeks up to month, related to the 
duration, therapeutic indication, and scope of the proposed clinical trial. The reproduction 
toxicology is performed again in two mammalian species (one non-rodent) in in vivo 
experiments and concerns the safety of pregnant humans. Before the availability of the 
results, all clinical trials are exclusively performed in male humans. The last set of toxicology 
studies is safety pharmacology. The core of safety pharmacology studies includes the 
assessment of effects on the cardiovascular, central nervous and respiratory system. The 
compiled resulting data show whether more investigations have to be undertaken to issue 
the safety profile of the drug. The most critical organs in terms of adverse effects are the 
organs excessively exposed to the drug or its metabolites. In the first instance, this adverse 
effect occurs mainly in the liver and the kidneys, as well as in the heart and lungs. Adverse 
effects that not be overcome, are usually a deathblow to the drug candidate. In general, 
adverse effects results represent the point at which mechanistic toxicologists become active. 
In a specific set of experiments, the toxicologist tries to reveal the mechanism and 
hazardousness of the observed adverse effect. If the mechanism can be clarified and ranked 
as reversible, monitorable, rodent specific and/or acceptable (e.g. by a safety margin), the 
development process can be continued. It cannot be denied that toxicology measurements 
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are enormously relevant parts of the drug discovery and development process and can 
greatly influence the progress of a potential drug candidate. However, it should be 
mentioned that toxicology is not a single discipline in the drug research process. For 
example, the preclinical department (DMPK) supports toxicology studies through a number 
of important results that it issues, to accumulate better knowledge of drug candidates and 
thus improved insight into adverse effect. However, an observation of an adverse effect in 
organs (e.g. liver), especially in the range of the considered therapeutic dose, is a serious 
event in the preclinical process and requires further investigation for the identification of the 
underlying mechanisms. Common sets of techniques are available, but do not represent a 
panacea for the analysis of toxicology findings. In any case, any additional information that 
permits a deeper insight into the toxicological mechanism can help to determine the 
progress of a drug candidate and can probably save resources.  
 
1.5.1 Drug-induced liver injury (DILI)  
Drug-induced liver injury (DILI) is an important health problem that can necessitate 
discontinuation of an essential drug, hospitalisation with intensive care, or even liver 
transplantation (85). In 80% of all cases, DILI is caused by direct, dose-dependent toxicity by 
an administered drug or its metabolites. Alternatively, immunologically mediated 
idiosyncratic toxicity may lead to liver injury (86, 87). Idiosyncratic hepatoxicity can lead to a 
drug being withdrawn from the market, even after launching and clinical trials. A prime 
example of such a drug was Rezulin (Troglitazone), which was withdrawn in 2000 due to the 
risk of serve idiosyncratic hepatoxicity (88, 89). Drugs that exhibit chemical (direct) 
hepatotoxicity have predictable dose-response curves and well characterised mechanisms of 
toxicity. Examples include the promotion of dysfunction in physiological pathways and finally 
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cell death by direct insult by chemically reactive compounds, induction of an apoptotic 
process, or infliction of cellular stress (90). The latter phenomenon is often observed in the 
context of oxidative or metabolic stress, where inhibition of the mitochondrial respiratory 
chain results in a release of reactive oxygen species (ROS) to an excessive level and depletion 
of ATP (91-93). Furthermore, certain drugs influence mitochondrial activity by inhibiting fatty 
acid β-oxidation (91), impairing mitochondrial DNA replication (94) or opening the 
mitochondrial permeability transition pore, which is unavoidably associated with cell death 
(95). All of the physiological dysfunctions mentioned above ultimately lead to hepatic tissue 
damage. If energy is available in the form of ATP, injured cells enter programmed cell death 
(apoptosis). If ATP sources are exhausted, cells follow the necrosis pathway, enhancing 
hepatic inflammation (96). 
As shown in Figure 6, the vast majority of hepatic portal blood is composed of blood from 
the gastrointestinal viscera (from the lower part of the oesophagus to the upper part of 
rectum) and to a smaller extents from the spleen (92). The portal vein system is responsible 
for directing blood and absorbed drugs to the liver in a concentrated form. Therefore, the 
liver plays a pivotal role in drug metabolism and detoxification and is consequently 
vulnerable to injury.  
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Figure 6. The hepatic portal system is comprised of veins from almost every part of the digestive tract, even 
from the lower oesophagus and the upper rectum. In this view, some organs have been removed to reveal 
the blood vessels. (from: Robert, A.: Anatomie und Physiologie, Dorling Kindersley Verlag 2011) 
In phase I metabolism, initially the hepatic cytochrome P450 system transforms mainly 
lipophilic drugs into water-soluble metabolites for excretion in bile or urine (97). These 
oxidative metabolism pathways are followed by a phase II metabolism pathway (98, 99). 
Phase II metabolism reactions are usually conjugation reactions to glucuronic acid, sulphate 
or glutathione and the resulting hydrophilic metabolites are excreted into plasma or bile via 
transporters located at the hepatocytes membrane. In order to avoid hepatotoxicity, the 
generation of phase I products should not exceed the capacity of the liver to detoxify them. 
For example, such an incapacity can arise with abuse of alcohol and ingestion of 
acetaminophen, even a customarily tolerable dose of acetaminophen can, under these 
conditions, result in severe liver injury (100). 
Resulting hepatic dysfunction is generally paralleled by a rise in biochemical liver markers 
such as alanine aminotransferase, alkaline phosphatase and/or bilirubin (101). These initial 
Introduction 
19 
indicators of hepatotoxicity, when observed during the drug discovery and development 
process, call for alert and necessitate mechanistic follow-up studies. Such studies are ideally 
based on the use of additional biomarkers as predictors and are time consuming and costly if 
performed in experimental animals (102). However, in view of the poor correlation between 
clinical findings of DILI and standard preclinical animal studies, such efforts remain a 
challenge and are a source of concern for investigators and regulatory authorities. Ongoing 
efforts are therefore directed towards the development of predictive in silico or in vitro 
models to gain better insight into mechanisms leading to DILI and to uncover potential risks 
in the drug research (103). One strategy to gain improved insight into toxicity is the use of 
cytosensor systems, where a silica-based sensor system allows online monitoring of 
metabolic activity in target cells in the presence of potentially toxic chemicals (104). Because 
drug-induced liver adverse effects are of great interest, I therefore decided to identify drug-
induced liver adverse effects in vitro to support mechanistic toxicology studies and thus drug 
research. 
 
1.6 Bioenergetic pathways, or, how a meal provides energy for 1014 cells 
All cellular work, all of the activities of life, requires energy either from ATP or from other 
energy related molecules. For this, cells store energy mainly in the form of chemical bonds 
(52, 55, 56). The intracellular metabolic pathways are a series of chemical reactions in the 
cell to break down substrates and synthesise new, energetic molecules. These pathways are 
important to maintain the homeostasis of an organism (52, 105). Several distinct but linked 
metabolic pathways are used by cells to transfer the energy released by breakdown of fuel 
molecules into ATP and other small molecules (e.g. NADH, FADH) that are used for further 
energy generation. Cellular respiration is the process in the cell that converts the energy 
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from nutrients into ATP, using molecular oxygen (O2) as an electron acceptor, and is divided 
into four different but tightly linked parts; i.e. glycolysis, oxidative decarboxylation of 
pyruvate, Krebs cycles and finally oxidative phosphorylation (52, 55, 56). Regarding the 
whole cellular respiration process from glycolysis to oxidative phosphorylation, a net of 38 
ATP molecules are produced from one molecule of glucose, whereas 38 ATP molecules is 
only a theoretical value. De facto, in reality this is reduced due to several minor influences 
such as slightly leaky inner mitochondrial membranes or the consumption of energy by 
transporting and providing substrates (pyruvate, phosphate, ADP) for the ATP synthesis 
(106). The energy generating process is very susceptible to modification and the real value of 
generated ATP is closer to 28 – 30 ATP molecules (107), but it is nonetheless an effective 
process to generate energy. However, exogenous variations can influence these sensitive 
processes significantly, thus recording O2 consumption and excretion of acidic metabolic 
products (CO2 and lactate) from these processes can be used as responsive parameters to 
detect minute alterations in cellular metabolism and respiration. 
 
1.7 The multiparametric cytosensor system  
Because the goal of this thesis was to develop a new technology for the pharmaceutical 
industry based on bioenergetic pathways, I used a multiparametric cytosensor system 
capable of monitoring the energy pathways of cells. Two similar systems for the 
identification of these parameters were used (Figure 7), i.e. the Bionas®1500, a single sensor 
chip system, and the Bionas®2500, which measures six cell-coated chips simultaneously. The 
multiparametric cytosensor system allows simultaneous measurement of several metabolic 
parameters of the specific cells grown on the silica-sensor chip. The core of the system 
Introduction 
21 
consists of the silica-sensor chip SC1000 (Figure 8), including the sensors for the real-time 
monitoring of the cell physiological parameters. 
 
Figure 7. (A) Photographic illustration of the Bionas®2500 system. (B) Schematic diagram of the flow system 
and dimensions for the sensor chip analysis, indicating the inlet and outlet (arrows) of the assay medium and 
the small incubation chamber with an effective volume of 1.4 µL or 5.7 µL, respectively. The sensor chip 
SC1000 forms the bottom of the reaction chamber, including the three different sensors. 
 
 
 
Figure 8. (A) Photographic representation of the silica-sensor chip SC1000. The silica-sensor chip has a 
surface area of 75 mm2. (B) The zoom-view depicts the integrated sensors, include one interdigitated 
electrode structures (IDES) for the measurement of cellular impedance, five ion sensitive field effect 
transistor (ISFET) sensors for the measurement of pH, and five Clark-type sensors for the measurements of 
oxygen concentration (pictures reproduced with permission of Bionas Ltd., Rostock, Germany) 
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The supply of the assay medium to the sensor chip was carried out in stop and go phases. 
During these “stop phases”, metabolic breakdown products of the cells (lactate and 
carbonate) were released into the assay medium and were allowed to accumulate, resulting 
in alterations of extracellular pH (reflecting metabolic/glycolytic activity) (Figure 9A) (108). 
Simultaneously, the change in oxygen concentration is recorded, which is an indication of 
cellular respiration activity (Figure 9B). Initial rates of extracellular acidification and 
respiration were calculated by changes in the slope in the stop phases and a linear 
regression analysis. The system records one raw data point every 10 s in the stop and go 
phases of an experiment. Impedance measurements were carried out continuously over the 
whole experiment to monitor cell adhesion and thus cell morphology, viability and 
membrane functionality (109).  
 
Figure 9. Representative raw data from an example of a multiparametric cytosensor system experiment. 
Cellular respiration of L-MDR1 cells is shown during several 2 min stop (pump off) and 2 min go (pump on) 
cycles (solid lines). Recorded data (square symbols) are plotted against time and include measurement of 
extracellular acidification (A) and oxygen concentration (B). The pH is proportional to a measured voltage (U) 
and the oxygen concentration is proportional to a measured current (I). Extracellular acidification (A) and 
cellular respiration (B) rates were calculated from the initial slope of each stop phase by a linear regression. 
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2 AIMS 
Because cellular activities require energy, the goal of this thesis was to develop a new 
technology for drug research based on the monitoring of cellular energy pathways. For this 
approach, different questions from three sections of drug discovery and development were 
explored and effective ways were sought to answer questions by utilising the cellular energy 
pathways. 
 
2.1 Real-time identification of P-glycoprotein substrates 
As described in section 1.3.2, the common techniques to identify substrates for P-gp in vitro 
suffer from several limitations and concerns in reliability (40-44). In view of these limitations, 
the aim of the project was to implement a new, label-free method to identify substrates of 
P-gp on-line in living cells by monitoring changes in cellular energy pathways. A further goal 
was to validate this assay as an effective and generic tool for the reliable identification of 
these P-gp substrates. Concerning the energy pathways, the regeneration of consumed ATP 
via cellular processes is coupled with the formation of carbon dioxide and lactate, which are 
released into the extracellular milieu as carbonic acid and lactic acid (108). Besides 
acidification, oxygen is consumed during ATP regeneration, resulting in a decrease in oxygen 
concentration in the extracellular environment. These two processes, i.e. oxygen 
consumption and extracellular acidification, are indicators of ATP regeneration and thus P-gp 
activity. Using a MDR1-overexpressing cell line, the objective was to develop a label-free and 
real-time analysis system for the identification of P-gp substrates in living cells. 
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2.2 Does the P2X7 receptor mediate effects on cellular metabolism upon ATP treatment? 
To investigate the effects of extracellular ATP on cell metabolism, I also used the 
multiparametric, cell-based sensor system to simultaneously monitor metabolic-related 
extracellular acidification rate (pH changes), cellular respiration (oxygen consumption), and 
cellular morphology and adhesion (impedance measurements) (108). In an initial set of 
experiments, the release of hydrogen peroxide from mononuclear blood cells exposed to 
exogenously applied ATP was explored, as a marker for metabolic activity. Results from 
these experiments were suspected of being linked with the purinergic P2X7 receptor.  
To investigate the role of extracellular ATP on cell metabolism associated with the purinergic 
P2X7 receptor, I further took advantage of a recombinant cell line expressing the P2X7 
receptor at high levels. This P2X7 cell line was used to analyse alterations in cell metabolism, 
mitochondrial respiration, and changes in cell shape upon the application of exogenously 
applied ATP.  
I subsequently verified the role of the P2X7 receptor by using of a specific P2X7 agonist (Bz-
ATP) and a selective P2X7 receptor antagonist. The effect of the antagonist on cell 
metabolism was investigated in terms of its ability to block P2X7 receptor-mediated ion flux, 
intracellular Ca2+ increase, and YoPro1 uptake. 
 
2.3 Identification of drug-induced adverse liver effects on human HepG2 cells 
I used the multiparametric, chip-based cytosensor system to determine physiological 
changes in a cell line overexpressing the drug efflux transporter P-gp (110) (section 2.1) and 
for the identification of metabolic changes after exogenous application of ATP to cells 
overexpressing the purinergic P2X7 receptor (section 2.2). In light of the sensitivity of such a 
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cytosensor system to deviations in the physiological parameters, the question arises as to 
whether this approach might be adapted to monitor the early onset of drug-induced 
hepatocellular damage in vitro.  
In view of the above, the aim of this thesis project was to implement and validate a cell-
based multiparametric cytosensor system to characterise DILI. For this approach, eight 
prototypic drugs known to be hepatotoxic in therapeutic use were investigated with respect 
to their toxicological potential on human hepatocarcinoma-derived HepG2 cells. The distinct 
differences in the mechanisms of hepatotoxicity and liver pathology were thoroughly 
considered during the selection of these eight drugs. The HepG2 cell line is frequently used 
as a model of liver cells (111, 112). In an additional control experiment, the metabolic 
activity of HepG2 cells was assessed and results derived from the mass spectrometry analysis 
were compared to previously published data (113-115). Emphasis was placed on the 
assessment of mitochondrial respiration, metabolic activity and/or morphological changes 
and cell adhesion as major markers of toxicity. Based on the nature of cellular response, 
different types of effects, including necrosis-like-, apoptosis-like cell death, and metabolic or 
oxidative stress, were discriminated.  
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3 MATERIAL AND METHODS 
3.1 Materials 
All chemicals were obtained in the highest available purity from Sigma-Aldrich (Buchs, 
Switzerland) and LGM Pharma (Boca Raton, Florida, US) unless otherwise indicated. 
Reference chemicals and drugs used in the studies are listed in Table 1. An overview of the 
cell culture media, supplements, and adjuvant used is given in Table 2. The P2X7 receptor 
antagonist, amiodarone, cyclosporine A, doxorubicin, isoniazide, and methotrexate were 
used as stock solutions in dimethyl sulfoxide (DMSO). Organic solvents concentrations did 
not exceed 1.0% (v/v) in any of the experiments. The MTT (3-(4, 5-dimethylthiazol-2-yl)-2, 5-
diphenyltetrazolium bromide) stock solution was prepared in phosphate buffered saline at a 
concentration of 5 mg/mL, and was then sterile-filtered and stored at 4 °C in the dark. Aside 
from common laboratory material, all materials used, cell lines, buffers, and solutions are 
mentioned in the related chapter. 
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Table 1. An overview of the compounds (i.e. drugs, antagonists, and agonists) investigated in the projects 
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Amiodarone HCl 681.8 DMSO  1.0, 5.0, 10, 15, 30 µM 
   
  
Cyclosporin A 1`202.6 DMSO  1.0, 3.0, 10, 30, 60 µM 
   
  
Doxorubicin HCl 580.0 Water  1.0, 5.0, 10, 25 µM 
   
  
Isoniazide 137.1 Water  0.1, 0.5, 1.0, 3.0, 5.0 mM 
   
  
Methotrexate hydrate 454.4 DMSO  1.0, 10, 50, 100, 200 µM 
   
  
D-Sorbitol 182.2 Water  0.001, 0.01, 0.1, 1.0, 5.0 mM 
   
  
Terfenadine 471.7 DMSO 5.0, 25 µM 
   
  
Valproic acid sodium salt 166.2 Water  0.5, 1.0, 3.0, 5.0, 10 mM 
        
a
 Stock solution adjusted to pH 7.4 using sodium hydroxide. 
Project Compound Molecular 
weight 
Solvent for 
stock solution 
Concentrations used  
in experiments with the 
sensor system 
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Caffeine 194.2 Water 10 µM 
   
  
Daunorubicin HCl 564.0 DMSO 1.0 µM 
   
  
Elacridar 563.6 DMSO 0.1 µM 
   
  
Fexofenadine HCl 538.1 DMSO 1.0 µM 
   
  
Loperamide HCl 513.5 DMSO 10 µM 
   
  
Propranolol HCl 295.8 Water 10 µM 
   
  
Quinidine HCl 378.9 Water 10 µM 
   
  
Verapamil HCl 491.1 Water 1.0, 5.0, 15, 50 µM 
        
P
2
X
7
 r
e
ce
p
to
r 
        
ATP 
a
 507.2 Water 0.005 - 5.0 mM 
    
Bz-ATP
 a
 715.4 Water 1.0, 10, 50, 100 µM 
   
  
P2X7 receptor antagonist 455.5 DMSO 10 µM 
        
     
 
Acetaminophen 151.2 Water  0.01, 0.1, 1.0, 5.0, 10 mM 
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3.2 Cell culture 
Cell culture work was carried out under standard biosafety level 2 conditions (116). Cell 
handling was performed in a microbiological safety cabinet (Skan, Allschwil, Switzerland) to 
reduce risk of contamination. All freshly prepared primary cells and cell lines grow as 
adherent cells in standard 75 cm2 tissue culture flasks (TPP AG, Trasadingen, Switzerland). 
With the exception of the primary rat cortical cells, all cells used were passaged by 
trypsination twice a week using a dilution factor ratio of 1:5 to 1:20. For this procedure, cells 
were rinsed with 15 mL pre-warmed PBS, followed by cell detachment with 0.25% 
trypsin-EDTA and dilution in the appropriate culture medium. Cell viability was analysed by a 
Vi-Cell XR cell viability analyser (Beckman Coulter, Krefeld, Germany), using a trypan blue 
exclusion test. Cells showing cell viability below 80% were rejected for use in experiments. 
The amount of cells used for experiments was calculated based on the viable cells. For 
optimal cell attachment, some cells require surface coating with poly-L-lysine, poly-D-lysine 
or fibronectin prior to experiments, according to the manufactures protocols. Briefly, 
surfaces were disinfected using 70% (v/v) aqueous ethanol, rinsed twice with PBS, and 
incubated for 3 h with the coating agents at 37 °C in a humidified atmosphere containing 
5% CO2. Coating agents were removed and surfaces were rinsed with PBS prior to the cell 
suspension being dispensed. 
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Table 2. An overview of the media, supplements, and adjuvants used in the cell culture. 
 
Media, Supplements, Adjuvants 
Catalogue 
number  
Supplier 
DMEM containing GlutaMAX™ 21885 
Life technologies TM, Basel, 
Switzerland 
Neurobasal™ medium 21103 
Medium 199 containing GlutaMAX™ 41150 
MEM containing GlutaMAX™ 21090 
MEM (10x) 21430 
Medium 199 (10x) 21180 
GlutaMAX™ Supplement (200 mM) 35050 
L-Glutamine 200 mM (100x) 25030 
Geneticin (G418), selective antibiotics (50 mg/mL) 10131 
Penicillin/streptomycin solution  
(10 kUnits/mL penicillin and 10 mg/mL streptomycin) 
15140 
Sodium pyruvate (100 mM) 11360 
Hanks`balanced salt solution (HBSS) (10x) 14065 
Hepes buffer solution (1 M)  15630 
Non-essential amino acids (100x) 11140 
B-27 supplement (50x) 17504 
Trypsin-EDTA (0.25% Trypsin, 1 mM EDTA) 25200 
Fluo-4-AM™, (1.0 mM solution in DMSO) F14202 
Heat-inactivated foetal bovine serum A15-104 
PAA Laboratories, Pasching, 
Austria 
Foetal calf serum 2-01F30-1 
BioConcept, Allschwil, 
Switzerland Penicillin/streptomycin solution  
(10 kUnits/mL penicillin and 10 mg/mL streptomycin) 
for mouse microglia BV2 cells 
4-01F00-H 
Colchicine (10 µg/mL) L6211 
Biochrom AG, Berlin,  
Germany 
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Table 2 (continued). An overview of the media, supplements, and adjuvants used in the cell culture. 
 
Media, Supplements, Adjuvants 
Catalogue 
number  
Supplier 
Poly-D-Lysine (0.01%) P6407 
Sigma, Buchs,  
Switzerland 
Poly-L-Lysine (0.01%) P4707 
Phosphate buffered saline (PBS),  
without Ca2+ and Mg2+ 
D8537 
Fibronectin from bovine plasma (1.0 mg/mL) F1141 
Papain (20 Units/mg protein) LK003178 
Worthington, Lakewood,  
NJ, US 
EBM® medium CC-3121 
Lonza Ltd., Walkersville, MD, US 
EGM® SingleQuots CC-4133 
Bovine brain extract (BBE) (9.0 mg/mL) CC-4098 
Hydrocortisone (1.0 mg/mL) CC-4036C 
Gentamicin/amphotericin solution 
(30 mg/mL gentamicin, 15 µg/mL amphotericin-B)  
CC-4081C 
Human embryonic growth factor (3.0 mg/mL) CC-4107C 
 
3.2.1 LLC-PK1 and L-MDR1 cells 
The human P-gp overexpressing cell line L-MDR1 derived from the porcine kidney epithelial 
cell line LLC-PK1 was obtained under license from The Netherlands Cancer Institute 
(Amsterdam, The Netherlands). Cells were maintained under standard cell culture conditions 
(section 3.2) and described previously (39, 40). Cells were cultivated at passage numbers 
12 – 26 in 75 cm2 cell culture flasks at 37 °C in Medium 199 with 2.0 mM GlutaMAX 
supplemented with 50 IU/mL penicillin, 50 μg/mL streptomycin and 10% (v/v) foetal bovine 
serum in a humidified atmosphere containing 5% CO2. L-MDR1 cells were subcultured in the 
presence of 150 ng/mL colchicine to maintain P-gp expression levels. Colchicine was omitted 
from medium 12 h prior to use in the experiments to avoid the development of other drug 
resistance mechanisms that could modify the action of P-gp (117). It has been shown that, 
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once in culture and induced, cells express constant levels of P-gp for up to at least 15 
passages (118). 
 
3.2.2 HUVEC cells 
Human umbilical vein endothelial cells were obtained from Lonza (CC-2517, Walkersville, 
MD, US) and maintained under standard cell culture conditions. Cells were maintained in 
EBM® medium with Clonetics EGM® SingleQuots supplemented with 2.0% (v/v) 
heat-inactivated foetal bovine serum, 1.0 µg/mL hydrocortisone, 36 µg/mL bovine brain 
extract, 3.0 ng/mL human embryonic growth factor, 30 µg/mL gentamicin, 15 ng/mL 
amphotericin-B, 50 IU/mL penicillin and 50 µg/mL streptomycin at 37 °C in a humidified 
atmosphere containing 5% CO2.  
 
3.2.3 Human mononuclear blood cells  
For the preparation of fresh mononuclear cells (lymphocytes, monocytes and macrophages), 
30 mL human blood containing 10% (v/v) citrate as anticoagulant were taken and 
mononuclear cells were isolated using a polymorphprep™ (Axis-Shield, Oslo, Norway) 
density centrifugation kit according to the manufacturer`s protocol. Briefly, in a 50 mL 
reaction tube, 15 mL of human blood were layered on 17 mL of the polymorphprep™ buffer 
(Axis-Shield, Oslo, Norway) and centrifuged at 500 g for 30 min at 22 °C. After gradient 
centrifugation, different bands of blood cells appear. The mononuclear cell band was 
transferred to a new 50 mL reaction tube and diluted with one equivalent of 0.45% (v/v) 
aqueous sodium chloride solution to restore physiological osmolarity. The solution was again 
centrifuged at 450 g for 18 min at 20 °C and the supernatant removed. Subsequently, the 
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cell pellet was reconstituted in 0.9% (v/v) aqueous sodium chloride solution and again 
centrifuged at 400 g for 10 min at 20 °C. Supernatant was removed and remaining red blood 
cells were hypertonically lysed by adding 9.0 mL demineralised water for 17 s and then 
centrifuged at 300 g for 10 min at 20 °C. The cell pellet after the last centrifugation step was 
reconstituted in 20 mL PBS and cell viability and concentration analysed by a Vi-cell XR cell 
viability analyser. Cell concentration was adjusted to 2 x 106 cells/mL and a 250 µL-aliquot of 
this cell suspension was dispensed into a 96-well plate and immediately used for 
experiments. 
 
3.2.4 P2X7 overexpressing HEK293 cells  
The human P2X7 (HEK-hP2X7) cell line generation was performed in the laboratories of 
Actelion Ltd. (Allschwil, Switzerland) according to established molecular cloning protocols. 
Specifically, RNA was extracted from human whole blood using the Qiagen RNeasy®kit 
(Qiagen, Hombrechtikon, Switzerland) according to the manufacturer’s instructions. 
Subsequently cDNA was generated (Superscript®II, Life technologies, Basel, Switzerland) and 
the human P2X7 gene (genebank ref. BC011913) was amplified and ligated into a 
pcDNA3.1 (+) vector. HEK293 cells (ATCC CRL–1573, Manassas, VA, US) were transfected 
with the pcDNA3.1 (+)hP2X7 plasmid using lipofectamine™2000 transfection reagent (Life 
Technologies, Basel, Switzerland) according to the manufacturer’s instructions. Following a 
24 h-exposure to DNA, cells were trypsinised and re-seeded at low density in the presence of 
0.25 mg/mL geneticin (G418). Geneticin resistant cells were then selected during two 
consecutive rounds of cloning by serial limiting dilution with visual inspection. Individual 
clones were screened for P2X7 expression by applying ATP and recording the resulting 
uptake of YoPro1. A specific cell clone was chosen based on RNA and protein expression. 
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Cells were cultivated at passage numbers 1 – 30 in 75 cm2 cell culture flasks at 37 °C in 
DMEM with 2.0 mM L-glutamine, supplemented with 50 IU/mL penicillin, 50 µg/mL 
streptomycin and 10% (v/v) heat-inactivated foetal calf serum in a humidified atmosphere 
containing 5% CO2. HEK-hP2X7 cells were cultured in the presence of 0.25 mg/mL geneticin 
(G418) to maintain P2X7 expression levels. It has been shown that, once in culture and 
induced, cells express constant levels of P2X7 for up to at least 30 passages. 
 
3.2.5 Mouse microglia BV2 cells 
A mouse microglia BV2 cell line for patch-clamp experiments was cultured under standard 
cell culture conditions. The cells were maintained in 75 cm2 cell culture flasks at 37 °C in 
DMEM with 2.0 mM GlutaMAX supplemented with 50 IU/mL penicillin, 50 µg/mL 
streptomycin and 10% (v/v) foetal calf serum in a humidified atmosphere containing 5% CO2. 
 
3.2.6 Primary Wistar rat cortical cells 
Freshly prepared cortical cultures originated from Wistar rat embryos 18 days 
post-gestation. After enzymatic cell dissociation with papain, the cells were resuspended and 
diluted to 3 x 105 cells/mL in neurobasal medium supplemented with 0.5 mM L-glutamine, 
2.0% (v/v) B27, 50 IU/mL penicillin and 50 µg/mL streptomycin. Fifty µL-aliquots of this 
suspension were dispensed into poly-D-lysine-coated 384-well micro BioCoat™ plates 
(Becton Dickinson, Basel, Switzerland) and incubated at 37 °C for a period of about 8 days in 
a humidified atmosphere containing 5% CO2. 
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3.2.7 Human hepatocarcinoma-derived HepG2 cells 
The human epithelial hepatocarcinoma-derived cell line HepG2 was obtained from the 
American Type Culture Collection (ATCC HB-8065, Rockville, MD, US) and was maintained 
under standard cell culture conditions (see section 3.2) and as described previously (119). 
Briefly, the HepG2 cells were cultivated at passage numbers 3 - 15 in 75 cm2 cell culture 
flasks at 37 °C in MEM with 2.0 mM GlutaMAX, supplemented with 1.0 mM sodium 
pyruvate, 1.0% (v/v) non-essential amino acids, 50 IU/mL penicillin, 50 µg/mL streptomycin 
and 10% (v/v) heat-inactivated foetal bovine serum in a humidified atmosphere containing 
5% CO2. 
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3.3 Methods 
3.3.1 Real-time monitoring of cell physiological parameters 
For the real-time measurements of physiological parameters, two cell-based sensor systems 
were used. The Bionas®1500 hosted one cell-coated chip for analysis, whereas the 
Bionas®2500 was able to measure six cell-coated chips simultaneously (Figure 7). The 
systems were used as described previously (110) with project related modifications 
(Table 3). 
 
Table 3. Conditions of the assays using the multiparametric cytosensor system 
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HepG2  
 
2500 2.0   5.7 56 3 3 1`140 
MEM (21430),  
0.1% FBS,  
1 mM sodium pyruvate,   
1% NEAA,  
25 IU penicillin,  
25 µg/mL streptomycin 
 
 
Prior to experiments, cells were detached by trypsination for approx. 4 min and cell viability 
analysed by a Vi-Cell XR analyser. Cells were then diluted in culture medium to reach the 
required cell amount by adding 0.35 mL of these cell suspensions to the pre-warmed sensor 
chips and incubating for at least 16 h prior to use. The core of the system consists of the 
Project Bionas 
system 
Cells per 
sensor chip  
Chip 
coating 
Effective 
chamber 
volume  
Flow rate  Stop 
cycle  
Go 
cycle  
Compound 
exposure 
time  
Cell line / 
assay medium 
composition 
 
 
[ x 10
5
] 
 
[µL] [µL/min] [min] [min] [min] 
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 LLC-PK1; L-MDR1 
1500 0.75 - 1.5   5.7 252 2 2 20 
Medium 199 (21180),  
2.0% FBS,  
0.3 mM GlutaMAX,  
50 IU penicillin, 50 µg/mL 
streptomycin 
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HEK293; HEK-hP2X7  
1500 2.0 
Fibro- 
nectin 
1.4 63 4 3 21 
MEM (21430),  
0.1% FBS,  
25 IU penicillin,  
25 µg/mL streptomycin 
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silica-sensor chip SC1000 (Figure 8) containing ion sensitive field effect transistor and Clark-
type sensors for the measurement of dynamic changes of acidification and oxygen 
consumption. Cell adhesion was monitored by means of impedance measurements using an 
interdigitated electrode structures circuit. The effective volumes of the reaction chamber (i.e 
the volume of the space between the surface of the sensor chip and the chamber lid) were 
either 1.4 µL or 5.7 µL (Table 3) and were determined by the distance (50 µm or 200 µm) 
between the flow head and the sensors chip surface (Figure 7). Cells were seeded directly 
onto the silica-sensor chip with or without prior surface coating according to the type of cells 
used in the experiments (Table 3). During analysis, assay medium (Table 3) was delivered to 
the cells at a constant flow rate (Table 3). The supply of assay medium was interrupted 
periodically, as described previously (110). These stop/go cycles were carried out throughout 
the entire experiment (divided into periods of medium exchange and periods without 
medium flow), during which the parameters were recorded. The duration of the stop and go 
cycles were project dependent and are defined in Table 3. During these “stop phases”, 
metabolic breakdown products of the cells (lactate and carbonate) were released into the 
assay medium and were allowed to accumulate, resulting in a change in extracellular pH 
(108). Extracellular oxygen concentrations were monitored in parallel. Initial rates of 
extracellular acidification and respiration were calculated by changes to the slope in the stop 
phases and a linear regression analysis. Recorded data were normalised to a reference value, 
which represented the baseline signal of a cell-coated chip prior to treatment with the 
compound. Impedance measurements were carried out continuously to monitor cell 
adhesion and thus cell morphology, viability, and membrane functionality (109). As a 
control, 0.2% Triton X-100 was added to the cells at the end of each experiment to induce 
cell membrane destruction and thus detachment of cells from the surface of the sensor chip. 
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The signals that were generated under these conditions were used to provide a reference 
signal from the cell-free sensor surface (0% baseline value) (109). These relative signals 
relate to a 0% control value of an empty sensor chip and to a 100% reference value 
representing the baseline signal of a cell-coated chip prior to compound treatment. 
The initialisation procedure of the sensor system prior to each experiment was carried out 
routinely, whereat the supply lines of the system were conditioned in a three-step 
procedure: disinfection with 70% (v/v) aqueous ethanol, flushing with an excess of PBS and 
rinsing with low-buffered assay medium. For the measurements, an assay medium with low 
buffer capacity was required (Table 3). Assay media were prepared from ten-fold 
concentrated stock media and the concentration of penicillin and streptomycin was halved, 
due to the reduced foetal bovine serum content and therefore more unbound antibiotics in 
the medium. The concentration of foetal bovine serum in the assay media did not exceed 
2.0% (v/v) to keep the buffer capacity of the FBS as low as possible. The assay media 
contained neither Hepes nor NaHCO3 and were adjusted to pH 7.4 using sodium hydroxide. 
Before use, the integrity of the cell monolayer covering the surface of the microsensor chip 
was verified using a Motic DM-39C reflected-light microscope (Motic Group Ltd., Hong Kong, 
China). Cell monolayers with a cellular confluence below 80% were rejected for use.  
Signals from the metabolic sensor chip were then recorded after a stabilisation phase of at 
least 3 h to acquire a constant baseline signal-to-noise ratio from the different sensors. 
Subsequently, treatment of compounds dissolved in assay medium (adjusted to pH 7.4 with 
sodium hydroxide) or drug-free running medium (control) was initiated. For those 
compounds for which stock solutions were prepared in other media, an equal amount of 
DMSO was added to the assay medium for initial stabilisation phase to avoid the detection 
of effects from DMSO. All compounds and their individual concentrations in the 
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multiparametric cytosensor system assays are listed in Table 1. Raw data were recorded by 
all sensors at intervals of 10 s to obtain one raw data point per ten seconds. From these data 
points, initial rates of acidification and cellular respiration were derived by linear regression. 
Compound treatment phases were followed by compound wash-out periods for detection of 
regeneration processes. After the experiment, impedance values were recorded following 
solubilisation of cells by 0.2% (v/v) Triton X-100. This control is used to compare cell 
monolayer integrity during the experiment with a reference value obtained from a cell-free 
sensor chip at the end of the experiment. This value represents, by definition, the 0% 
reference control value. 
 
3.3.2 Western blot detection of P-glycoprotein 
A Western blot analysis was carried out to confirm the presence of P-gp in L-MDR1 and its 
absence in parental LLC-PK1 cells. LLC-PK1 (passage no. 25) and L-MDR1 (passage no. 14) 
cells were harvested by trypsination (5 min) at approx. 80% confluence, viability was 
determined by a Vi-cell XR analyser, and diluted in PBS to reach a final cell concentration of 
6 x 105 cells/mL. The cell suspension was transferred in a pre-cooled 2 mL S-homogeniser 
(Sartorius, Göttingen, Germany), placed on ice, and homogenised for fifteen cycles. The 
separation of the cell proteins was achieved by sodium dodecylsulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE). For the SDS-PAGE analysis, 12 µL of the homogenised cell 
suspension was mixed with 3 µL loading buffer (2.3% sodium dodecylsulphate, 72.5 mM 
Tris(hydroxymethyl)-amminomethane (pH 6.8), 17.3% glycerol, 10 mg/mL bromophenol 
blue) and incubated for 5 min at 95 °C for protein denaturation. The samples were 
subsequently transferred to a NuPAGE® 4 - 12% Bis-Tris precast gel (Life technologies, Basel, 
Switzerland) for protein electrophoresis. The SDS-PAGE was carried out in MOPS 
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(4-morpholinepropanesulfonic acid) buffer (Life technologies, Basel, Switzerland) using the 
XCell-SureLock™ aperture (Life technologies, Basel, Switzerland) according to the 
manufactures protocol. In addition to the samples, 5 µL of the Precision-Plus™ protein 
standard (BioRad Laboratories, Hercules, California, US) was added as a molecular weight 
marker. A current of 170 V was applied for approx. 1 h to the SDS-PAGE for electrophoretic 
protein separation. Subsequently the proteins were transferred to a Protran® nitrocellulose 
(NC) membrane (0.45 µm pore size, Schleicher & Schuell, Dassel, Germany) by means of an 
iBlot®Dry blotting system (Life technologies, Basel, Switzerland) according to the 
manufactures instruction protocol. All regions of the NC membrane, that did not containing 
proteins were saturated by incubation of the NC membrane with blocking milk (10% skim 
milk powder, 1.0% bovine serum albumin, 150 mM NaCl, 10 mM Tris-HCl (pH 7.4) and 0.3% 
Tween 20) over night at 4 °C. The primary mouse monoclonal MDR1-G1 (sc-13131, 
SantaCruz Biotechnology, Santa Cruz, CA, US) and the anti--actin (A1978, Sigma, Buchs, 
Switzerland) antibodies were added to the blocking buffer (1:1`000 each, v/v) and incubated 
at room temperature under gentle agitation for 1 h. After three washings with western-wash 
buffer (3.0 g/L bovine serum albumin, 150 mM NaCl, 10 mM Tris-HCl (pH 7.4), 0.05% 
Triton X-100) for 10 min each step, the secondary antibody (goat-anti-mouse IgG-HRP, cat. 
no. sc-2005, SantaCruz Biotechnology, Santa Cruz, California, US) was added (1:5`000, v/v) to 
the blocking milk and then applied to the NC membrane. After 1 h incubation under gentle 
agitation and room temperature the NC membrane was washed three times with 
Western-wash buffer, as described above. For the analysis of the proteins, the NC 
membrane was incubated for 1 min with a 1:1 (v/v) mixture of the Western-lightning-ECL™ 
chemiluminescence reagents (NEL101 and NEL102, PerkinElmer, Wellesley, MA, US) and 
transferred to a photosensitive Kodak BioMax™ Light film (Kodak, Rochester, NJ, US). The 
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film was exposed to the NC membrane for 1 min at room temperature and then developed 
by the Curix 60 tabletop processor (Agfa, Mortsel, Belgium). 
 
3.3.3 Metabolic activity of human mononuclear blood cells 
Production of cellular hydrogen peroxide (H2O2) was analysed by the Amplex®Red assay 
obtained from Life technologies (Basel, Switzerland) after application of the P2X7 agonists 
(ATP or Bz-ATP) to human mononuclear blood cells. Oxidation of glucose by glucose oxidase 
resulted in the generation of hydrogen peroxide, which is coupled to the conversion of the 
Amplex®Red reagent to fluorescent resorufin in the presence of horseradish peroxidase. 
Briefly, 5 x 105 human mononuclear blood cells (section 3.2.3) were placed in the wells of a 
96-well plate and incubated with 50 µM Amplex®Red and 0.1 U/mL horseradish peroxidase 
for 0.5 h at 37 °C in Krebs Ringer phosphate solution (145 mM NaCl, 5.7 mM sodium 
phosphate, 4.9 mM KCl, 0.5 mM CaCl2, 1.2 mM MgSO4, and 5.5 mM glucose), protected from 
light. After adding ATP (0 – 4.0 mM) or Bz-ATP (0 – 400 µM) to the cells, the fluorescence 
was quantified by means of a microplate reader (Synergy MX, BioTek®, Luzern, Switzerland) 
at excitation and absorbance wavelengths at 550 nm and 600 nm, respectively. Background 
fluorescence, determined using a reaction without mononuclear cells, was subtracted from 
each value. From these preliminary results, the optimal ATP concentration was determined 
as 1.0 mM and this was used again for the determination of hydrogen peroxide release, in 
the presence of the selective P2X7 receptor antagonist (0 - 25 µM). 
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3.3.4 Dynamic mass redistribution assay 
The Corning Epic® system (Corning Inc., Tewksbury, MA, US) was used, consisting of a 
temperature controlled unit, an optical detection unit, and an on-board robotic liquid 
handling device. The Epic® system measures changes within the cell monolayer in the index 
of refraction, which can be ligand-induced upon mass redistribution. HUVEC cells (section 
3.2.2) were detached by trypsination for approx. 5 min and analysed by a Vi-cell XR cell 
viability analyser. Cells were then diluted in culture medium to reach a final concentration of 
4 x 105 cells/mL medium. A 30 µL-aliquot of this cell suspension was transferred to a 
fibronectin-coated 384-well Epic® microplate containing 10 µL HUVEC medium (section 
3.2.2) and incubated at 37 °C for 20 h in a humidified atmosphere containing 5% CO2 to 
achieve a confluent monolayer. Each microplate well bottom contained a resonant 
waveguide grating biosensor. Prior to the experiment, the medium was replaced by 30 µL 
HBSS buffer supplemented with 20 mM Hepes and 0.06% (w/v) bovine serum albumin and 
kept for 2 h in the Epic® reader at a constant temperature of 26 °C for equilibration. The 
sensor microplate was then analysed and an initial baseline curve was recorded. 
Subsequently, the ATP solution in the assay buffer was dispensed into the microplate at a 
concentration range of 0 to 5.0 mM and the dynamic mass redistribution was monitored for 
4`000 s. Control experiments were performed in the absence of ATP under otherwise 
identical conditions. In these controls, the volumes of the ATP-containing solutions were 
replaced by assay buffer. 
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3.3.5 YoPro1 uptake analysis 
Uptake of membrane-impermeable fluorescent dyes, such as YoPro1, is a hallmark of early 
downstream signalling by the P2X7 receptor and was used as a means of identifying the P2X7 
receptor antagonists in human embryonic kidney cells expressing the P2X7 receptor at high 
levels (120, 121). 
HEK-hP2X7 cells (section 3.2.4) were detached by trypsination (0.5 ml per 75 cm2 dish), 
which lasted two minutes and were analysed by a Vi-cell XR cell viability analyser. Cells were 
then diluted in medium (section 3.2.4) without geneticin to a final concentration of 
2 x 105 cells/mL and a 50 µL-aliquot of this cell suspension was transferred to a poly-L-lysine 
pre-coated black-wall, clear-bottom 384-well-plate and incubated 48 h at 37 °C in a 
humidified atmosphere containing 5% CO2. Medium was removed from cells and assay 
buffer containing 0.5 µM YoPro1 was added into the wells. Solutions of the antagonist were 
prepared by serial dilutions of a 10 mM DMSO solution into PBS. Each concentration was 
represented in duplicate. For IC50 measurements, ten concentrations were measured (10 µM 
being the highest concentration followed by nine serial dilution steps 1:3, v/v). The cells 
were incubated with the selective P2X7 receptor antagonist and ATP at a final concentration 
of 250 µM for 90 min. During this period, four time points were taken. Each time point 
comprised the average of several measurements made within a few seconds. Fluorescence 
was measured in the FLIPR®-Tetra (fluorescent imaging plate reader; Molecular Device, 
Sunnyvale, CA, US) using the filters appropriate for YoPro1 fluorescence (excitation 485, 
emission 530). The FLIPR®-Tetra was equipped with Molecular Devices Screen Works system 
control software to define and run experimental protocols. The affinity of the antagonist was 
determined at the EC50 concentration of the agonist (250 µM ATP for HEK293 cells 
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overexpressing human recombinant P2X7 receptor). For IC50 measurements, the maximum 
intensity is plotted against the concentration of the antagonist to determine IC50 values. 
 
3.3.6 Fluo-4-AM calcium measurements 
Calcium transients were determined using a Tetra high-throughput fluorescence imaging 
plate reader (Molecular Devices, Sunnyvale, CA, US) at room temperature. Wistar rat 
primary cortical cells (section 3.2.6), at day eight in culture, were loaded with 1.0 µM Fluo-4-
AM in HBSS (pH 7.4) containing 20 mM Hepes. Cells were washed once with HBSS 10 min 
before recording. After a 15 min pre-incubation with 0.01 - 10 µM of the selective P2X7 
receptor antagonist, the P2X7 agonist Bz-ATP was applied to the cells at a final concentration 
of 250 µM. In control incubations, Bz-ATP was replaced by DMSO in equal amounts used in 
the Bz-ATP incubations. Data points were collected every one second and analysed using the 
plate reader specific software (Molecular Devices, version 2.0.0.24, Sunnyvale, CA, US) and 
IGOR software (IGOR Pro, version 6.12A, Oregon, US). 
 
3.3.7 Electrophysiology 
For patch-clamp experiments, mouse microglia BV2 cells (section 3.2.5) were analysed in the 
whole cell patch-clamp configuration (122). Patch electrodes were filled with intracellular 
buffer containing 120 mM KF, 20 mM KCl, 1.0 mM EGTA (ethylene glycol-bis(aminoethyl 
ether)-tetraacetic acid) and 10 mM Hepes adjusted to pH 7.2 with potassium hydroxide. 
Recordings were done at room temperature in external buffer containing 147 mM NaCl, 
2.0 mM KCl, 0.3 mM CaCl2, 10 mM Hepes and 12 mM D-glucose adjusted to pH 7.4 with 
sodium hydroxide. At a constant holding potential of -70 millivolt, 100 µM Bz-ATP were 
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applied in the absence or presence of different concentrations of the selective P2X7 receptor 
antagonist by a computer-controlled application system. Agonist-induced steady-state 
currents were corrected for leakage, and concentration-response curves were fitted to 
averaged current amplitudes derived from 3 – 4 cells. 
 
3.3.8 MTT cell viability assay 
HepG2 cells were seeded in 96-well plates at a density of 5 x 104 cells/well and were cultured 
as described above (section 3.2.7). Twenty-four hours after seeding, medium was removed 
and 100 µL aliquots of cell culture medium containing the test compounds were added to 
each well in triplicate. Control cells were incubated in the presence of 1.0% (v/v) DMSO 
(100% viability control). After 24 h, cell culture medium was replaced by 100 µL cell culture 
medium containing 10% (v/v) MTT stock solution. Cells were incubated for additional 2 h at 
37 °C. In a final step, the cell culture medium was discarded and reduced MTT, which is 
present as water-insoluble formazan dye crystals, was dissolved by adding 20 µL of 3.0% 
(v/v) sodium dodecylsulphate solution in water, and 100 µL of a 40 mM hydrochloric acid in 
isopropanol. Optical density was measured at 550 nm using a Spectramax® M2 plate reader 
(Molecular Devices, Sunnyvale, CA, US). 
 
3.3.9 Metabolic activity of human hepatocarcinoma-derived cells, HepG2 
Acetaminophen and amiodarone were incubated with human hepatocarcinoma-derived 
HepG2 cells (section 3.2.7) to confirm activity in phase I and phase II metabolism. Since the 
metabolic pathways and the metabolites of these two compounds in the liver were already 
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elucidated, these compounds were used as prime examples to confirm metabolic activity of 
HepG2 cells.  
For the determination of metabolic activity of HepG2 cell, 19 h-incubations with amiodarone 
and acetaminophen were performed. HepG2 cells were detached by trypsination for 5 min 
and analysed by a Vi-Cell XR cell viability analyser. Cells were then diluted in culture medium 
to a nominal density of 1.25 x 106 viable cells/mL and 400 µL aliquots of this suspension were 
dispensed into 24-well plates and incubated at 37 °C for a period of about 20 h in a 
humidified atmosphere containing 5% CO2 for cell attachment. 
At the end of the pre-incubation period, the medium was removed from each well and 
replaced by 200 µL of pre-warmed (37 °C) incubation medium containing amiodarone or 
acetaminophen at final concentrations of 20 µM. Triplicate wells were sampled after 19 h of 
incubation by addition of 200 µL of ice-cold acetonitrile and transfer of the entire well 
content into 2 mL cryovials. Samples were stored frozen at -20 °C pending analysis. Prior 
LC-MS analysis, samples were centrifuged at 20`800 g for 5 min at 4 °C and supernatant 
were submitted to LC-MS analysis without further treatment. Control incubations in the 
absence of cells were performed in parallel.  
The analytical system consisted of two Shimadzu HPLC pumps LC-20AD XR (Shimadzu, 
Reinach, Switzerland) equipped with a membrane degasser (DGU-20A), a Shimadzu system 
controller CBM-20A, a Thermo Scientific (San Jose, CA, US) photodiode array detector 
ACCELA™, a Shimadzu autosampler model SIL-30AC, and a LTQ-Orbitrap Velo Pro™ (Thermo 
Electron, San Jose, CA, US). 
The chromatographic separation of amiodarone and acetaminophen and their metabolites 
were achieved on a Phenomenex Luna®C18(2) column (250 x 4.6 mm, 5 µm, 100 Å) at 30 °C 
with a flow rate of 1.0 mL/min. Mobile phases consisted of 0.1% (v/v) formic acid in water 
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(phase A) and acetonitrile (phase B). The autosampler temperature was set to 4 °C. The 
applied gradient for the separation of the test compounds and their metabolites is described 
below: 
 
 
 
For the analysis of parent drug and metabolites, a full scan, high resolution LTQ-Orbitrap 
Velo Pro™ was used (Thermo Electron, San Jose, CA, US). The analysis was performed in 
positive ion mode and a mass range of 100 to 1`000 m/z. High resolution reconstructed ion 
chromatograms of potential metabolites were generated using mass tolerance of 
10 parts per million (ppm) and Xcalibur® software package (Version 2.1.0, Thermo Electron, 
San Jose, CA, US). Photodiode array detection (PDA) was used in parallel in the wavelength 
range of 200 to 300 nm. 
 
3.3.10 Data recording, analysis and statistics 
The evaluations as well as the kinetics and statistical calculations were performed using 
GraphPad Prism® software (Version 5.04, GraphPad Software Inc., La Jolla, CA, US), Bionas® 
data analyser software (Versions 1.22 and 1.66, Bionas GmbH, Rostock, Germany), 
OriginPro® (Version 7.5, OriginLab®, Northampton, MA, US) and Microsoft® Office 
Excel 2007. Each experiment was performed at least in triplicates. Results are expressed as 
the mean ± SEM or means with 63% or 95% confidence interval (CI). Statistical significances 
were estimated by unpaired t-tests and designated to *p < 0.05, **p < 0.01, and 
***p < 0.001. 
  
Time [min] 0 20 25 26 35 
Phase B [%] 5 95 95 5 stop 
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4 RESULTS 
4.1 Identification of P-glycoprotein substrates 
In this part of the thesis, the multiparametric cytosensor system (Figure 7) was used for 
real-time identification of P-gp substrates in human P-gp overexpressing LLC-PK1 cells 
(L-MDR1). The cells used in the study were preliminarily analysed to assess the expression 
level of P-gp using Western blot analysis technique.  
 
4.1.1 P-glycoprotein levels in LLC-PK1 and L-MDR1 cells 
The level of P-gp in parental LLC-PK1 and human MDR1-transfected cells (L-MDR1) was 
determined by Western blot detection. LLC-PK1 cells in culture at passage 25 and L-MDR1 
cells in culture at passage 14 were used to assess the levels of P-gp. Cell concentrations of 
both cell lines were adjusted to 6 x 106 cells/mL and subsequently homogenised. Identical 
aliquots of the resulting suspensions were transferred for protein separation by 
electrophoresis, followed by an electrical transfer of the proteins to a NC membrane. The NC 
membrane was incubated simultaneously with two specific monoclonal antibodies for the 
identification of P-gp (170 kDa) and total actin (42 kDa) levels. Beta-actin was used as a 
loading control and helped to determine whether the samples were loaded equally across all 
lanes and served to display the effective transfer of protein during Western blotting. 
Beta-actin is a suitable loading control due to its general expression across all eukaryotic cell 
types (123). Comparing the intensity of the loading control (Figure 10), the -actin bands in 
both lanes indicate equal levels of actin in LLC-PK1 and L-MDR1 cells. An intense signal at 
170 kDa was detected, indicating the presence of high levels of P-gp in the L-MDR1 cells. In 
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contrast to the L-MDR1 cells, no band at 170 kDa was detected in the lane with LLC-PK1 cell. 
The presence of high P-gp levels in L-MDR1 cells, and the absence of P-gp in LLC-PK1 cells 
was confirmed by the Western blot, and I therefore went on to use the cells in the 
multiparametric cytosensor system. Parental LLC-PK1 cells were assessed to be P-gp 
deficient and used as a control cell line in all further experiments of this project.  
 
Figure 10. Western blot analysis of P-gp (170 kDa) levels in parental LLC-PK1 cells and human MDR1 
transfected L-MDR1 cells. A 12 µL aliquot of a cell suspension containing 6 x 106 cells/mL was added to each 
lane for protein separation. After electrophoretic blotting of the proteins over to nitrocellulose membrane, 
P-gp was detected by a monoclonal antibody MDR1-G1 and visualised by staining with a secondary goat-anti-
mouse IgG-HRP antibody, which is responsible for chemiluminescence. The -actin staining was used as a 
loading control for better comparison of the analysed total protein levels. Position and size of the molecular 
weight marker are indicated. 
4.1.2 Real-time identification of P-glycoprotein substrates 
The multiparametric cytosensor system was used as an analytical tool for the real-time 
monitoring of changes in extracellular acidification (pH-changes), cell respiration (oxygen 
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concentration) and cell adhesion (cell impedance). The sensor system assay was optimised 
with respect to maximal stimulation amplitudes to allow for a sensitive and reliable 
recording of signals. Important assay parameters included the use of an assay medium with 
a low buffer capacity supplemented with 2.0% (v/v) foetal bovine serum albumin. Optimal 
cell densities were in the range of 0.75 to 1.5 x 105 attached cells per chip and the effective 
volume of the reaction chamber (i.e. the effective volume of the 200 µm space between the 
surface of the sensor chip and the chamber lid) was 5.7 µL.  
During measurements, the flow of assay medium was periodically interrupted for two 
minutes. After each measuring period, the incubation chamber was flushed for another two 
minutes with assay medium before a new measuring cycle was initiated. Cell viability was 
measured during the entire experiment and deviations were in the range of ± 20% over a run 
time of 1`500 min for all experiments of this project. A representative pattern of the cellular 
viability in all experiments of this study is given in Figure 11. 
 
Figure 11. Representative pattern of impedance curves recorded with L-MDR1 cells (blue) and LLC-PK1 cells 
(red) up to 1`600 min compiled from two different experiments. The arrows indicate the release of death 
cells from the chip after Triton X-100 treatment. 
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In a first set of experiments, activity of P-gp was monitored in the presence of verapamil (a 
P-gp substrate (40, 124)) and the negative control caffeine (non-P-gp substrate (125)). 
Experiments were initiated as soon as a stable baseline metabolic rate was attained (100% 
threshold in Figure 12). Extracellular acidification rates, as well as respiration rates were 
identified and correlated with P-gp activation (Figure 12, phase 1 of the experiment). After a 
regeneration phase of approx. 100 min P-gp activity was inhibited by adding 100 nM 
elacridar (Figure 12, phase 2). Subsequent addition of again 10 µM verapamil (Figure 12, 
phase 3) showed no further stimulatory effects, neither in extracellular acidification nor in 
respiration rates. Elacridar alone decreased the basal levels of extracellular acidification and 
respiration rates of almost 25% (Figure 12, phase 2) with subsequent stabilisation at the 
reduced basal activity level. At the end of the experiment (Figure 12), reference 0% signal-
levels of the cell-free microsensor chip were achieved by the addition of 0.2% (v/v) 
Triton X-100. Cell viability was recorded during the entire experiment and was in the range 
of the acceptable deviations. 
 
Figure 12. Stimulation of P-gp overexpressing L-MDR1 cells in the presence and absence of the P-gp inhibitor 
elacridar. Phase 1: stimulation of L-MDR1 cells with 10 μM verapamil results in an increase in the 
extracellular acidification rate (red, circles) and an increase in the oxygen consumption rate (green, 
triangles). Phase 2: addition of 100 nM elacridar after a wash-out phase. Phase 3: addition of 10 μM 
verapamil in the presence of 100 nM elacridar. At the end of the experiment: Triton X-100 (0.2%, v/v) 
treatment to obtain the 0% reference value of the empty sensor chip. Depicted is a representative pattern of 
n = 3 experiments. 
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Different concentrations of verapamil (1.0 - 50 µM) were analysed using L-MDR1 cells 
(Figure 13, solid symbols) and the Michaelis-Menten kinetics were calculated. Stimulation of 
P-gp by verapamil showed saturation at high concentrations and was characterised by a KM 
value of 0.92 ± 0.12 μM (calculated based on extracellular acidification rates (red), 
mean ± SEM, n = 4) and 4.9 ± 2.7 μM (calculated based on respiration rates (green), 
mean ± SEM, n = 4). Vmax values for extracellular acidification rates (57.4 ± 1.6% as compared 
to 0% control, mean ± SEM, n = 4) were twice as high as the corresponding Vmax values for 
respiration rates (25.4 ± 5.2% as compared to 0% control, mean ± SEM, n = 4). At substrate 
concentrations of 50 μM verapamil, a sudden drop in extracellular acidification rates as well 
as in respiration rates was observed.  
 
Figure 13. Stimulation of P-gp in the presence of different concentrations of verapamil. Extracellular 
acidification (red, circles) and oxygen consumption (green, triangles) in P-gp overexpressing L-MDR1 cells 
(solid symbols) and parental, LLC-PK1 (open symbols, dotted lines) cells measured as a function of increasing 
concentrations of verapamil. Solid lines: curve fitting using a Michaelis–Menten type kinetics model. Signals 
obtained at a verapamil concentration of 50 μM were rejected for kinetic calculations, due to substrate 
inhibition effects. Level of significance between L-MDR1 and parental LLC-PK1 controls: ***p < 0.001, n = 4.  
 
Cell viability was measured during the entire experiment and deviations were in the range of 
± 13% over an experimental run time of 1`500 min. In a separate set of control experiments 
(Figure 13, open symbols), P-gp-deficient LLC-PK1 cells were incubated in the presence of 
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verapamil and did not show any stimulation effects in either extracellular acidification rates 
or respiration rates. 
Figure 14 showed the identification of P-gp substrates using the extracellular acidification 
parameter because this shows higher sensitivity. Seven market drugs were analysed with 
respect to their potential to modulate P-gp activity. Activation of P-gp was expressed as the 
ratio between acidification rates measured during and immediately before stimulation of 
L-MDR1 cells (delta acidification rates). Propranolol, caffeine, quinidine, verapamil, and 
loperamide were used at a substrate concentration of 10 µM, while daunorubicin and 
fexofenadine concentrations were reduced to 1.0 µM. Both, propranolol and caffeine, 
known not to interact with P-gp, were used as negative controls. Compared with the two 
negative controls, all P-gp substrates were identified with statistical significance. Cellular 
impedance and thus cellular viability were not affected by the test compounds in the 
concentration ranges used. 
 
Figure 14. Identification of P-gp substrates using the multiparametric cytosensor system in combination with 
P-gp expressing L-MDR1 cells. Extracellular acidification rates were determined in the presence and absence 
of test compound (10 μM final substrate concentration with the exception of 1.0 μM of daunorubicin and 
fexofenadine). Ratios of acidification rates before and during stimulation (Δ Acidification) are shown. Data 
are means ± SEM, n > 3. Levels of statistical significant difference between acidification rates in unstimulated 
or stimulated cells are *p < 0.05, **p < 0.01 or ***p < 0.001. 
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Figure 15 showed the control experiments in LLC-PK1 cells with a set of test compounds. No 
effects of these test compounds were detected under the same experimental conditions. 
Cell viability was again within the limit of acceptable deviations.  
 
 
Figure 15. Control experiments demonstrating absence of stimulatory effects in parental LLC-PK1 cells. 
Caffeine (phase 1), verapamil (phase 2), loperamide (phase 3), quinidine (phase 4) and paclitaxel (phase 5) 
did not induce extracellular acidification in P-gp deficient LLC-PK1 cells. All compounds were tested at a 
substrate concentration of 10 μM. Triton X-100 (0.2%, v/v) treatment (phase 6) at the end of the experiment 
was used to obtain the 0% reference value of the cell-free sensor chip. Depicted is a representative pattern. 
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4.2 Purinergic P2X7 receptor mediates metabolic changes upon ATP treatment 
Metabolic activity of human mononuclear blood- and HUVEC cells after treatment with 
extracellular ATP was assessed.  
Many metabolic processes in cells lead to the formation of hydrogen peroxide, which can be 
used as a marker for metabolic activity (126). Therefore, I investigated the effect of 
exogenously applied ATP on the release of hydrogen peroxide from mononuclear cells, 
freshly prepared from human donor blood. Cells were treated with ATP and supernatant was 
analysed after 20 min. ATP induced a strong, concentration-dependent increase in hydrogen 
peroxide release with a half-maximal effective concentration of 558 ± 5.0 µM (mean ± SEM, 
n = 3), as depicted in Figure 16.  
 
Figure 16. Rate of hydrogen peroxide formation in human mononuclear blood cells. The formation of 
hydrogen peroxide was analysed in mononuclear blood cells upon exogenously applied ATP, as a marker for 
metabolic activity in cells. Human mononuclear blood cells were exposed to ATP at the concentration range 
of 0 to 4.0 mM. Fluorescence was measured with a fluorescence microplate reader using excitation at 
550 nm and fluorescence absorbance at 600 nm. Background fluorescence, determined for a control reaction 
with no H2O2, was subtracted from each value. The half-maximal effective concentration was 
EC50 = 558 ± 5.0 µM (n = 3). 
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Extracellular ATP mediates its effect by activating ionotropic or metabotropic receptors. 
Usually, activity of metabotropic receptors is linked to changes in cellular metabolism, thus 
the name 'metabotropic'. However, in this case, the concentration response curve for ATP 
induction of hydrogen peroxide release, with the EC50 value above 500 µM, did not fit with 
the ATP sensitivity of the twelve known metabotropic P2Y receptors. Only P2X7 receptors 
have such low sensitivity to extracellular ATP (71). It is probable that non-linear mechanisms 
between receptor activation and hydrogen peroxide release could explain such an 
observation. Nevertheless, when the effect of extracellular ATP was tested on dynamic mass 
redistribution in HUVEC cells, a similar concentration-response correlation with an EC50 of 
933 ± 110 µM (mean ± SEM of three experiments with n = 2 replicates) (Figure 17) was 
observed.  
 
Figure 17. The mass redistribution of human umbilical vein endothelial cells (HUVEC) was assessed in the Epic 
system to identify changes upon treatment with exogenously applied ATP. Cells showed significant 
concentration-dependent effects in the Epic, indicating strong morphological changes with an 
EC50 = 933 ± 110 µM (mean ± SEM of three experiments with n = 2 replicates). The larger figure showed one 
of the three representative raw data sets. The smaller figure depicts the calculation of the EC50 derived from 
the raw data. 
I therefore tested whether the selective and potent P2X7 receptor antagonist was able to 
block the ATP-induced effect on human mononuclear blood cells. 
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The P2X7 receptor antagonist elicited a moderate inhibition of the hydrogen peroxide 
formation in human mononuclear blood cells with a half-maximal inhibition (IC50) of 
3.0 ± 0.5 µM (mean ± SEM, n = 3), indicating that P2X7 receptors at least partially mediate 
the observed metabolic effects (Figure 18).  
 
Figure 18. P2X7 receptor antagonist effect on hydrogen peroxide levels in human mononuclear blood cells. 
Inhibition of ATP-induced hydrogen peroxide release by the selective P2X7 receptor antagonist. The P2X7 
receptor antagonist was used from 0 to 25 µM and the IC50 was 3.0 ± 0.5 µM (mean ± SEM, n = 3). 
In addition, Bz-ATP, which selectively activates the P2X4- and P2X7 receptors (71), was able 
to mimic the results of observations with ATP in the hydrogen peroxide release assay 
(Figure 19), corroborating my hypothesis that P2X7 receptors at least partially link 
extracellular ATP with intracellular metabolic pathways. The EC50 could not be calculated, 
because the hydrogen peroxide release did not reach a plateau at the highest concentrations 
of Bz-ATP used, showing room for increasing metabolic levels.  
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Figure 19. The formation of hydrogen peroxide was analysed in human mononuclear blood cells upon 
treatment with P2X7-specific extracellular Bz-ATP, as a marker for increased metabolic activity in cells. 
Human mononuclear blood cells were exposed to Bz-ATP in the concentration range of 0 to 400 µM. 
Fluorescence was measured with a fluorescence microplate reader using excitation at 550 nm and 
fluorescence absorbance at 600 nm. Background fluorescence, determined for a control reaction without 
H2O2, was subtracted from each value (n = 3). 
 
I subsequently went on to study more specifically how P2X7 receptors influence cellular 
metabolism using the label-free multiparametric sensor system. I used the Bionas®1500 to 
analyse changes in oxygen concentration, extracellular acidification, and cell impedance. 
Enhanced metabolic activity of cells requires increased oxygen consumption for 
regeneration of energy, which is detectable during the stop phases by a decrease in oxygen 
concentration. Moreover, toxicity associated with mitochondrial inhibition or uncoupling of 
the proton circuit is detectable by the alteration of oxygen consumption. The sensor system 
was optimised with respect to maximal stimulation amplitudes, as described previously 
(110). This allows for sensitive and reliable recording of the signals. Optimal cell density was 
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2 x 105 attached cells per fibronectin-coated chip and an effective incubation chamber 
volume of 1.4 µL (i.e. the effective volume of the 50 µm space between the surface of the 
sensor chip and the chamber lid). Viability of cells was monitored continuously by 
measurement of cellular impedance. Continuous deviations in the range of about ± 1.2% per 
hour from initial values were considered acceptable and were attributed to cell proliferation 
or cell release from the chip.  
 
The multiparametric cell-based sensor system detects metabolic alterations upon Bz-ATP 
treatment.  
Both human P2X7-overexpressing HEK293 cells (HEK-hP2X7) and parental HEK293 cells with 
no expression of P2X7 were monitored for alterations in physiological cell parameters to 
assess the influence of exogenously applied Bz-ATP to intracellular metabolic pathways. The 
results obtained with HEK-hP2X7 cells were compared to those of parental HEK293 cells 
(127). HEK-hP2X7 cells immediately responded to Bz-ATP treatment in a concentration-
dependent manner. In agreement with previous findings (128), cell morphology changed, 
with a maximum effect being reached at 100 µM Bz-ATP (13% above control with parental 
HEK293 cells) (Figure 20A). In comparison to HEK-hP2X7, parental cells HEK293 showed only 
negligible effects on the impedance sensor, predominantly at lower concentrations of 
Bz-ATP. One-hundred µM Bz-ATP applied to parental cells showed reduced amplitude. 
Furthermore, in HEK-hP2X7 cells the metabolic activity (Figure 20C) and cellular respiration 
(Figure 20B) increased in a concentration-dependent manner upon Bz-ATP treatment. An 
obvious effect was observed in metabolic and respiratory activity on HEK-hP2X7 cells at the 
highest Bz-ATP concentration (100 µM). Compared to parental HEK293 cells, a reduction of 
23% in cellular respiration was observed at 100 µM Bz-ATP, while metabolic activity was 
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increased by 24% relative to parental HEK293 cells. This particular effect at 100 µM Bz-ATP 
with HEK-hP2X7 cells was absent in parental HEK293 cells (Figure 20B, C).  
 
Figure 20. Concentration-dependant stimulation effects of HEK-hP2X7cells (black, solid lines) and parental 
HEK293 cells (blue, dotted lines) upon treatment with the P2X7 specific agonist Bz-ATP analysed by the 
sensor system. (A) Compared to parental HEK293 cells, the human P2X7 overexpressing HEK293 cells showed 
a more significant increase in cellular impedance up to 100 µM Bz-ATP, while parental HEK293 cells initiate a 
reduction of impedance effects at concentrations above 50 µM. (B) Cellular respiration showed a 
concentration-dependent increase in HEK-hP2X7 at concentrations equal to and below 50 µM Bz-ATP 
compared to parental HEK293 cells. Bz-ATP treatment at 100 µM demonstrates the toxicological effect of 
Bz-ATP by strong inhibition of the respiratory activity. This effect is most likely a consequence of pore 
dilatation and Ca2+-influx. Respiration of the parental HEK293 cells was almost stable at all concentrations of 
Bz-ATP. (C) The metabolic activity of the HEK-hP2X7 cells was again activated upon Bz-ATP treatment. A 
remarkable amplitude is depicted at 100 µM Bz-ATP and is a domino effect, due to a lack of ATP generation 
via oxidative phosphorylation. Statistical significance: *p < 0.05, **p < 0.01, ***p < 0.001, n = 4. 
The morphological changes upon Bz-ATP treatment are an indication of ligand binding to the 
human P2X7 receptor (128). Therefore, the calculation of an EC50 was carried out in HEK-
hP2X7 cells (Figure 21). Activation of P2X7 by Bz-ATP showed saturation at high 
concentrations and was characterised by an EC50 value of 9.6 ± 0.8 µM (mean ± SEM, n = 5).  
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Figure 21. Stimulation of P2X7 in the presence of different concentrations of Bz-ATP. Morphological changes 
in HEK-hP2X7- (black circles) and parental HEK293 (blue squares) cells were measured as a function of 
increasing Bz-ATP concentrations. The solid line shows the curve fitting using an enzyme kinetic model. 
Strong morphological changes were observed with an EC50 of 9.6 ± 0.8 µM (mean ± SEM, n = 5). The level of 
significance between HEK-hP2X7 and parental HEK293 controls for concentrations above 1.0 µM was 
**p < 0.01, n = 5. 
 
The results of the multiparametric cytosensor system (Figure 20) confirm the correlation 
between exogenously applied Bz-ATP and the triggering of intracellular metabolic pathways 
via the P2X7 receptor. Therefore, the inhibition of these alterations in order to investigate 
the role of P2X7 in cellular metabolism was analysed using the specific P2X7 receptor 
antagonist. In a further set of experiments with the sensor system, the inhibition of the 
effects triggered by Bz-ATP on the HEK-hP2X7 cells was assessed. 
 
Figure 22 shows the inhibitory effect of the P2X7 receptor antagonist on metabolic activity, 
cellular respiration, and morphology of HEK-hP2X7- and parental HEK293 cells using 50 µM 
Bz-ATP. All previously observed stimulatory effects on HEK-hP2X7 cells were inhibited by the 
Results 
61 
P2X7 receptor antagonist, suggesting that P2X7 is important for Bz-ATP-induced intracellular 
metabolic changes. The inhibition of the Bz-ATP-induced effects observed in the P2X7 
overexpressing cells were absent in parental HEK293 cells (Figure 22). 
 
Figure 22. Inhibition experiments using HEK-hP2X7- (black column) and parental HEK293 (white column) 
cells. P2X7 were stimulated by preliminary treatment with 50 µM Bz-ATP, followed by an inhibition of Bz-
ATP induced effects with 10 µM of the P2X7 receptor antagonist in the presence of 50 µM Bz-ATP. (Table 4 
provides an overview of the inhibition potency). After a wash-out period of at least 4 h after the inhibition 
step, the cells were again stimulated with 50 µM Bz-ATP to assess regeneration and reactivation processes. 
Statistical significance between the stimulation effects and inhibition was, for all three sensors, *p < 0.05, 
n = 4. 
 
Comparative pharmacology of P2X7 receptor-mediated effects on cellular metabolism, 
calcium-, and dye influx.  
The P2X7 receptor was activated by Bz-ATP in patch-clamp experiments on a P2X7 receptor-
expressing mouse microglia BV2 cell line and was characterised by an EC50 value of 
197 ± 2.3 µM (mean ± SEM, n = 5). The P2X7 receptor antagonist was also able to inhibit, 
with similar affinity, Bz-ATP-induced currents measured in patch-clamp experiments with the 
mouse microglia cell line, BV2. Bz-ATP induced stable inward currents at a holding potential 
of -70 millivolt that were blocked by the P2X7 receptor antagonist with an IC50 of 2.1 µM 
(95% CI 1.8 - 2.5 µM, n ≥ 5) (Figure 23). 
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Figure 23. Comparison of the raw current signal patterns after stimulation and inhibition of P2X7 expressing 
mouse microglia BV2 cells. (A) The P2X7 receptor specific patterns of 100 µM Bz-ATP-induced current signals 
in mouse microglia BV2 cells with an EC50 of 197 ± 2.3 µM (mean ± SEM, n = 5). (B) Indicates the current 
signal pattern of BV2 cells stimulated with Bz-ATP in the presence of the P2X7 receptor antagonist. (C) 
Depicts the inhibition curves with the selective P2X7 receptor antagonist on membrane currents in mouse 
microglia BV2 cells. Bz-ATP was used at 100 µM, which is in the concentration range of the estimated EC50 
values for the agonist. One-hundred µM Bz-ATP induced a current in mouse microglia BV2 cells that was 
blocked by the P2X7 receptor antagonist with an IC50 of 2.1 µM (95% CI 1.8 - 2.5 µM, n ≥ 5). 
 
I additionally questioned how closely the P2X7 receptor-mediated effects on cell 
morphology, extracellular acidification, and cellular respiration are linked to channel 
function. P2X7 receptors are ion channels permeable to mono- and divalent cations and, 
upon longer activation, to larger ions such as YoPro1. This dye was used to monitor Bz-ATP 
and P2X7 receptor antagonist pharmacology in the HEK-hP2X7 cells used in the experiments 
with the multiparametric cytosensor system. YoPro1 influx into HEK-hP2X7 cells upon 
stimulation with Bz-ATP for 45 min was measured and was able to antagonise Bz-ATP effects 
completely with an IC50 of 11.2 nM (95% CI 9.6 - 13.2 nM, mean of three experiments with 
n = 2 replicates) (Figure 24).  
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Figure 24. YoPro1 dye permeability measurements using ATP as agonist and the selective P2X7 receptor 
antagonist. Uptake of the YoPro1 dye in human P2X7 overexpressing HEK293 cells was inhibited by the P2X7 
receptor antagonist and was characterised by an IC50 value of 11.2 nM (95% CI 9.6 - 13.2 nM, mean of three 
experiments with n = 2 replicates; depicted is a representative pattern). 
When measuring Ca2+ influx via P2X7 receptors using a calcium-sensitive fluorescent dye in 
primary cortical cultures from rat embryonic brains, the P2X7 receptor antagonist inhibited 
Bz-ATP-induced Ca2+ influx with an IC50 of 3.2 µM (95% CI 2.8 - 3.7 µM, n ≥ 4) (Figure 25).  
 
Figure 25. Intracellular Ca2+ increase by Bz-ATP stimulation of P2X7 receptor antagonist in rat cortical cells. 
(A) Depicted is a section of the 384-well plate and the recorded currents for the P2X7 receptor antagonist 
and the control (DMSO). (B) The remaining current was measured and showed concentration-dependent 
effects with an IC50 of 3.2 µM (95% CI 2.8 - 3.7 µM, n ≥ 4).  
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All of these experiments, with recombinant cells overexpressing the human P2X7 receptor as 
well as the rodent P2X7 receptors, showed that the pharmacology of P2X7 receptor-
mediated metabolic changes are well in line with the pharmacology of more direct 
physiological effectors upon receptor activation (Table 4). 
 
Table 4: Summary of the inhibitory affinity of the P2X7 receptor antagonist 
 
Assay Cells Agonist a 
[µM] 
Selective P2X7 
receptor 
antagonist [µM] 
IC50  / 
% inhibition 
H2O2 release mononuclear 
blood cells 
1`000 0 - 25 3.0 µM 
     
YoPro1 uptake HEK-hP2X7 3`000 3.8 x 10
-5 - 10 11.2 nM 
     
Fluo-4-AM rat cortical 250 0.01 - 10 3.2 µM 
     
Patch-clamp mouse microglia 100 0.3 - 10 2.1 µM / 
96%b 
     Sensor system 
respiration 
HEK-hP2X7 50 10 92% 
     Sensor system 
acidification 
HEK-hP2X7 50 10 77% 
     Sensor system 
impedance 
HEK-hP2X7 50 10 77% 
          
a Hydrogen peroxide (H2O2) release and YoPro1 uptake assays were performed with ATP, all other assays 
with Bz-ATP; b at 10 µM selective P2X7 receptor antagonist. 
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4.3 Detection of drug-induced liver toxic effects using HepG2 cell 
Metabolic activity of HepG2 cells.  
In control experiments, the metabolic activity of HepG2 cells was assessed by means of 19 h 
incubations with acetaminophen and amiodarone (20 µM each). Metabolites were detected 
using high-resolution liquid chromatography coupled with mass spectrometry in positive ion 
mode. Acetaminophen incubations with HepG2 cells resulted in the formation of an oxidised 
metabolite (m/z 168), NAPQI (m/z 150), and two phase II metabolites (a cysteine adduct at 
m/z 271 and a glucuronic acid conjugate at m/z 328). In incubations with amiodarone, the 
major metabolite was desethylamiodarone (m/z 618) accompanied by a hydrated- 
(m/z 648), a dehydrated- (m/z 644) and an oxidised metabolite (m/z 662). Figure 26 and 
Figure 27 showed the mass spectrometry patterns of acetaminophen and amiodarone, the 
identified metabolites, and the putative metabolic pathways. 
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Figure 26. (A) High resolution ion chromatograms in ion positive mode and photodiode array detector 
pattern (200 - 300 nm) of acetaminophen (ACAP, m/z 152) and its metabolites. Acetaminophen was 
incubated for 19 h with HepG2 cells. (B) Putative metabolic pathway of the acetaminophen metabolites 
detected in the 19 h incubation with HepG2 cells.  
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Figure 27. (A) High resolution ion chromatograms in ion positive mode and photodiode array detector 
pattern (200 - 300 nm) of amiodarone (m/z 646) and its metabolites. Amiodarone was incubated for 19 h 
with HepG2 cells. (B) Putative metabolic pathway of the amiodarone metabolites detected in the 19 h 
incubation with HepG2 cells.  
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Experimental setup of the multiparametric cytosensor system for analysis of liver 
toxicological effects.  
Changes in oxygen concentration, extracellular acidification, and cell impedance were 
monitored in real-time using the multiparametric cytosensor system. The experimental 
set-up was optimised to achieve maximal sensitivity to physiological alterations (Figure 7B, 
Table 3). Important assay parameters included the use of an assay medium (Table 3) with a 
low buffer capacity, which was additionally supplemented with 0.1% (v/v) heat-inactivated 
foetal bovine serum albumin. Optimal cell density was determined as 2 x 105 viable HepG2 
cells per chip. Minimal required cell viability, estimated by a trypan blue dye exclusion test, 
was 90%. The effective volume of the incubation chamber, i.e. the volume of the space 
between the surface of the sensor chip and the chamber lid, was 5.7 µL and was determined 
by the distance (200 µm) between the flow head and the sensor chip surface (Figure 7B). 
This minimal volume enhances the responsiveness of the system with respect to alterations 
in pH and oxygen partial pressure. Signals from cell respiration, acidification, and impedance 
were recorded after an initial stabilisation phase of 3 h. Subsequently, cells were exposed to 
test compounds for 19 h, followed by a regeneration phase of 2 h to detect cell 
regeneration. After the experiment, baseline signals of the cell-free cytosensor chips (i.e. 0% 
reference signal) were recorded after solubilisation of cells using a non-ionic detergent 
(Triton X-100). Viability of cells was monitored continuously by measurements of cellular 
impedance. Thus, signals from the three sensor types were recorded relative to initial 
conditions (100% reference signal) and 0% background signal. Eight marketed drugs were 
used at, above, and below their clinically relevant plasma concentrations to study 
hepatotoxic effects in vitro (Table 5). 
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Table 5: Characteristics and toxicological profiles of reference drugs used in the present toxicology project. 
 
Drug Indication  
(Cmax, range of 
therapeutic plasma 
concentration) 
Concentration 
range in the 
experiments 
Mechanism of 
toxicity 
Reactive 
metabolites 
Liver pathology 
Acetaminophen 
 
NSAID 
a
  
0.1 mM 
(129, 130) 
 
0.01 - 10 mM 
GSH depletion,  
mitochondrial 
toxicity 
(131-133) 
N-acetyl-p-
benzoquinone 
imine (NAPQI), 
other quinones 
Hepatocellular 
degeneration 
Amiodarone 
 
Antiarrythmic 
2.1 µM 
(134) 
 
1.0 - 30 µM 
ROS formation,  
mitochondrial 
toxicity 
(135-137) 
Desethyl-
amiodarone 
Steatosis, 
hepatocellular 
death 
Cyclosporine A 
 
Immunosuppresant 
1.5 µM 
(138) 
 
1.0 - 60 µM 
Covalent binding  
to microsomal 
proteins, ROS 
formation,  
oxidative stress, 
(133) 
Reactive 
metabolites 
 
Cholestasis 
Doxorubicin 
 
Anticancer 
1.9 µM 
(139) 
 
1.0 - 25 µM 
DNA intercalation, 
ROS formation,  
oxidative stress, 
mitochondrial 
toxicity 
(140, 141) 
Semiquinone 
radical 
Hepatocellular 
death 
Isoniazide 
 
Antibacterial 
0.11 mM 
(142) 
 
0.1 - 5.0 mM 
Oxidative stress,  
GSH depletion 
 (133, 143-146) 
Hydrazine, 
reactive acetyl 
species 
Steatosis, 
necrosis, 
hepatocyte and 
vasculature 
damage 
Methotrexate 
 
Anticancer 
up to 1150 µM;  
Immunosuppressant 
0.4 µM 
(147, 148) 
 
1.0 - 200 µM 
Inhibition of 
biosynthetic 
pathways,  
metabolic stress 
(149-152) 
Polyglutamated 
methotrexate 
Fatty infiltration, 
fibrosis, cirrhosis 
D-Sorbitol 
 
Laxative 
70 µM 
(153) 
0.001 - 
5.0 mM 
none none none 
Terfenadine 
 
Antihistamine 
4.5 nM 
(154) 
 
5.0 - 25 µM; 
Modulation of Ca2+ 
homeostasis, ROS 
formation, 
apoptosis-inducer 
(155, 156) 
 
unknown Cholestasis, 
hepatocellular 
death 
Valproic acid 
 
Anticonvulsant 
0.6 mM 
(157) 
 
0.5 - 10 mM; 
Oxidative stress, 
altered 
mitochondrial 
β-oxidation and  
oxidative 
phosphorylation,  
GSH/NAC
b depletion 
(91, 133, 158, 159) 
Acyl 
glucuronides, 
2-N-propyl-4-
pentenoic acid 
Necrosis, 
steatosis, 
cholestasis 
a Non-steroidal anti-inflammatory drug; b N-acetylcysteine 
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Effect of D-sorbitol on HepG2 cells.  
D-sorbitol, known to be well tolerated even at high concentrations and non-toxic, was used 
as a negative control (160). D-sorbitol (Figure 28) showed no relevant effects in the 
multiparametric cytosensor system at concentrations from 0.001 mM to 5.0 mM. A small but 
continuous increase in cellular respiration, reaching 110 - 120% of the control values, was 
detected at all concentrations. 
 
Figure 28. Patterns of cytosensor signals upon stimulation of HepG2 cells with D-sorbitol. Cells were 
incubated with the indicated concentrations of D-sorbitol. Using the multiparametric cytosensor system, 
three physiological parameters were monitored on-line: cell impedance being an indicator of cell 
morphology/adhesion, cellular respiration based on oxygen consumption, and metabolic activity resulting in 
extracellular acidification. The grey areas indicate the initial stabilisation and final regeneration periods, 
which are carried out in the absence of test compound. Control incubation in the absence of test compound 
was normalised to 100%. The patterns depict means of n ≥ 3 experiments. 
Effect of acetaminophen on HepG2 cells.  
Acetaminophen was used in a concentration range of 0.01 mM to 10 mM (Figure 29) and 
induced concentration-dependent effects in the multiparametric cytosensor system at all 
considered parameters over a 19 h incubation period. The impedance was indicative of 
shrinking and retraction of cells, reflected by a maximal drop to 80% from baseline values at 
10 mM acetaminophen within the first 70 min after addition of the compound. It then 
remained at around 80% to 90% for the remaining incubation time. Impedance was 
reversible in the regeneration phase, reaching baseline levels similar to the initial values 
prior to acetaminophen treatment. Reduction of cell respiration was detected immediately 
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after acetaminophen application. Maximal reduction was observed at 20 min after drug 
application reaching 40% of baseline values and was constant until the end of drug 
treatment. Conversely, at the same time, metabolic activity increased in a concentration-
dependent manner up to 130% (10 mM) and remained constant at this level over six hours 
before it returned to initial baseline levels. These effects were partially reversible during the 
regeneration phase, reaching values equal to those prior to drug treatment. In the MTT test, 
cell viability was significantly decreased (Table 6) showing a reduction to 80% and 62% in 
viability at 1.0 mM and 10 mM acetaminophen, respectively.  
 
 
Figure 29. Patterns of cytosensor signals upon stimulation of HepG2 cells with acetaminophen. Cells were 
incubated with the indicated concentrations of acetaminophen. Using the multiparametric cytosensor 
system, three physiological parameters were monitored on-line: cell impedance being an indicator of cell 
morphology/adhesion, cellular respiration based on oxygen consumption, and metabolic activity resulting in 
extracellular acidification. The grey areas indicate the initial stabilisation and final regeneration periods, 
which are carried out in the absence of a test compound. Control incubation in the absence of test 
compound was normalised to 100%. The patterns depict means of n ≥ 3 experiments. 
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Table 6. Cellular viability of HepG2 cells determined after 24 h incubation by the MTT assay. Values are 
means ± SEM (n = 3 of two independent sets of experiments) as compared to untreated control cells (100% 
viability). Level of significance (Student's t-test as compared to 100% control): **p ≤ 0.01, ***p ≤ 0.001. 
 
  
Compound % Viability  
(statistical significance) 
Concentration 
Acetaminophen 101.4 ± 0.7  
80.3 ± 0.3 (***) 
61.8 ± 0.3 (***) 
0.01 mM 
1.0 mM 
10 mM 
Amiodarone 100.2 ± 3.2 
95.7 ± 0.6  
107.9 ± 5.9 
1.0 µM 
10 μM 
30 μM 
Cyclosporine A 87.1 ± 5.3 
101.0 ± 0.8 
81.8 ± 2.6 (**) 
1.0 µM 
10 μM 
60 μM 
Doxorubicin 70.2 ± 3.9 (***) 
61.3 ± 1.2 (***) 
53.5 ± 1.8 (***) 
1.0 µM 
10 μM 
25 μM 
Isoniazide 97.1 ± 2.6 
99.5 ± 1.8 
102.9 ± 0.8 
0.1 mM 
1.0 mM 
5.0 mM 
Methotrexate 79.3 ± 1.4 (***) 
70.3 ± 2.5 (***) 
79.3 ± 0.8 (***) 
1.0 µM 
50 μM 
200 μM 
Valproic acid 101.9 ± 2.0  
89.0 ± 1.4 (**) 
85.2 ± 1.8 (**) 
0.5 mM 
3.0 mM 
10 mM 
Terfenadine (control for 
cytotoxicity) 
98.9 ± 6.3 
1.4 ± 0.2 (***) 
5.0 μM 
25 μM 
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Effect of amiodarone on HepG2 cells.  
Amiodarone caused intense changes in the multiparametric cytosensor system experiments 
(Figure 30). These changes were proportional to the concentrations used, which covered a 
range of 1.0 µM to 30 µM. Concentrations below 10 µM amiodarone did not influenced 
cellular physiology. However, pronounced effects were observed at concentrations equal to 
and above 10 µM. Three hours after amiodarone application, cytotoxicity and cell death 
were evident by a persistent decrease in cell impedance. Dying cells were released from the 
sensor chip and, at the end of the drug treatment period, only 16% (approx. 32`000 cells) of 
the initial cell number remained. At concentrations of 10 µM and above, amiodarone 
affected mitochondrial respiration and metabolic activity non-reversibly. The respiration 
curve at 30 µM amiodarone described a steep drop until 280 min post-treatment with 30% 
residual cell respiration, followed by a levelling-off to 15% at the end of the incubation 
period. The metabolic activity at 15 µM and 30 µM amiodarone increased with a maximal 
amplitude of 150% at 400 min post-treatment. At 30 µM amiodarone, this boost in 
metabolic activity changed into a sustained reduction until the end of the drug-treatment, 
with only 7% residual metabolic activity. In the MTT assay, amiodarone had no statistically 
significant effect on HepG2 cell viability at all concentrations of the MTT assay (Table 6).  
 
Figure 30. Patterns of cytosensor signals upon stimulation of HepG2 cells with amiodarone. Cells were 
incubated with the indicated concentrations of amiodarone. Using the multiparametric cytosensor system, 
three physiological parameters were monitored on-line: cell impedance being an indicator of cell 
morphology/adhesion, cellular respiration based on oxygen consumption, and metabolic activity resulting in 
extracellular acidification. The grey areas indicate the initial stabilisation and final regeneration periods, 
which are carried out in the absence of a test compound. Control incubation in the absence of test 
compound was normalised to 100%. The patterns depict means of n ≥ 3 experiments. 
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Effect of cyclosporine A on HepG2 cells.  
Cyclosporine A was analysed at concentrations up to 60 µM and showed no obvious effects 
with respect to cell impedance (Figure 31). In cell respiration, concentrations below 30 µM 
showed no obvious effects in the first 400 min of treatment, followed by a small increase in 
cell respiration to 110% of baseline values. A decrease to 60% was monitored within the first 
400 min after application of 30 µM and 60 µM cyclosporine A, followed by a nearly complete 
recovery of respiratory activity (90%) at the end of the treatment period. The decrease in 
respiration at 30 µM and 60 µM went in parallel with an increase in metabolic activity up to 
110%. Along the time course, the metabolic activity was continually reduced to 90% at the 
end of the cyclosporine A incubation. The MTT assay showed a statistically significant 
reduction of 18% in cell viability at the highest concentration of 60 µM (Table 6). No effects 
were observed in the MTT assay at concentrations below 60 µM. 
 
 
Figure 31. Patterns of cytosensor signals upon stimulation of HepG2 cells with cyclosporine A. Cells were 
incubated with the indicated concentrations of cyclosporine A. Using the multiparametric cytosensor system, 
three physiological parameters were monitored on-line: cell impedance being an indicator of cell 
morphology/adhesion, cellular respiration based on oxygen consumption, and metabolic activity resulting in 
extracellular acidification. The grey areas indicate the initial stabilisation and final regeneration periods, 
which are carried out in the absence of a test compound. Control incubation in the absence of test 
compound was normalised to 100%. The patterns depict means of n ≥ 3 experiments. 
 
Effect of doxorubicin on HepG2 cells.  
Cells treated with up to 25 µM doxorubicin were found to have stable impedance during the 
experiments (Figure 32). In contrast, mitochondrial respiration was directly affected and 
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reacted with a sudden, concentration-dependent drop after drug application. At 25 µM 
doxorubicin, cell respiration diminished to 46% within 230 min, followed by a constant and 
non-reversible reduction to 30% during the remaining incubation period. Simultaneously, 
metabolic activity was reduced in a concentration-dependent- and non-reversible manner. 
Doxorubicin initiated a sustained decrease in metabolic activity at 390 min post-application. 
At the end of the incubation period, the metabolic activity was in the range of 75% and 90% 
for doxorubicin concentrations equal to and above 5.0 µM and 1.0 µM, respectively. The 
24 h incubations of doxorubicin in the MTT assay indicate an impairment of cell viability 
(Table 6) showing a 61% and 54% reduction in viability for 10 µM and 25 µM doxorubicin, 
respectively. 
 
Figure 32. Patterns of cytosensor signals upon stimulation of HepG2 cells with doxorubicin. Cells were 
incubated with the indicated concentrations of doxorubicin. Using the multiparametric cytosensor system, 
three physiological parameters were monitored on-line: cell impedance being an indicator of cell 
morphology/adhesion, cellular respiration based on oxygen consumption, and metabolic activity resulting in 
extracellular acidification. The grey areas indicate the initial stabilisation and final regeneration periods, 
which are carried out in the absence of a test compound. Control incubation in the absence of test 
compound was normalised to 100%. The patterns depict means of n ≥ 3 experiments. 
Effect of isoniazide on HepG2 cells. 
Isoniazide was used in a concentration range of 0.1 mM to 5.0 mM. After applying isoniazide 
to HepG2 cells, a non-reversible and sustained reduction to 90% in impedance was observed 
until the end of the incubation period. An initial increase in cell impedance was detected at 
the highest concentration (5.0 mM), reaching a maximum of 110% at 400 min post-
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application (Figure 33). Immediately after drug application, mitochondrial respiration 
reduced continually during the entire incubation period and remained at levels of 60 - 80% 
for all concentrations used. Metabolic activity was not affected and remained stable during 
all experiments. There was also no impact on cell viability as determined by the MTT assay 
(Table 6), with a viability of 103% at 5.0 mM isoniazide. 
 
Figure 33. Patterns of cytosensor signals upon stimulation of HepG2 cells with isoniazide. Cells were 
incubated with the indicated concentrations of isoniazide. Using the multiparametric cytosensor system, 
three physiological parameters were monitored on-line: cell impedance being an indicator of cell 
morphology/adhesion, cellular respiration based on oxygen consumption, and metabolic activity resulting in 
extracellular acidification. The grey areas indicate the initial stabilisation and final regeneration periods, 
which are carried out in the absence of a test compound. Control incubation in the absence of test 
compound was normalised to 100%. The patterns depict means of n ≥ 3 experiments. 
Effect of methotrexate on HepG2 cells.  
Methotrexate was investigated at concentrations ranging from 1.0 µM to 200 µM. The two 
highest concentrations of methotrexate (100 µM and 200 µM) initiated a reduction of 
impedance at 80 min post-application, described by a sustained decrease to 86% of baseline 
values at the end of the incubation (Figure 34). This reduction was not reversible during the 
regeneration phase, which indicates cell death and was corroborated by observations in the 
MTT assay, where cellular viability was reduced to 79% at 200 µM (Table 6). The 
mitochondrial respiration curves at the two highest concentrations described an initial 
decrease to 78% during the first 320 min after application, followed by a persistent increase, 
reaching 125% at the end of the incubation. With the exception of the initial decrease, 
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treatment with 50 µM methotrexate showed similar curves, reaching 145% of the cell 
respiration signal at the end of the incubation. Metabolic activity was inhibited in a 
concentration-dependent manner 30 min after drug treatment, with a maximal reduction to 
70% at 200 µM, and was subsequent maintained at levels between 60% and 80%. In contrast 
to cellular respiration, metabolic activity was restored after the removal of the drug, 
reaching levels of around 90%.  
 
Figure 34. Patterns of cytosensor signals upon stimulation of HepG2 cells with methotrexate. Cells were 
incubated with the indicated concentrations of methotrexate. Using the multiparametric cytosensor system, 
three physiological parameters were monitored on-line: cell impedance being an indicator of cell 
morphology/adhesion, cellular respiration based on oxygen consumption, and metabolic activity resulting in 
extracellular acidification. The grey areas indicate the initial stabilisation and final regeneration periods, 
which are carried out in the absence of a test compound. Control incubation in the absence of test 
compound was normalised to 100%. The patterns depict means of n ≥ 3 experiments. 
Effect of valproic acid on HepG2 cells.  
Valproic acid was used in the concentration range of 0.5 mM to 10 mM. An increase to 112% 
in cellular impedance was observed during the first six hours of treatment with 10 mM 
valproic acid (Figure 35). After 640 min of treatment with 3.0 - 10 mM valproic acid, dying 
cells detached from the sensor chip, indicated by a constant decrease in cell impedance. Half 
of the initial cell amount (1 x 105 cells) remained on the sensor chip at the end of the 
incubation period with 10 mM valproic acid. Signals obtained from cell respiration sensors 
were concentration-dependent. The respiration curve described a sudden, steep drop to 
52% at 10 mM valproic acid, followed by a bell-shaped curve with maximal amplitude of 
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153% at 820 min post-application. At the end of the drug incubation period, cell respiration 
was 130% at 10 mM valproic acid. Metabolic activity and cell respiration were reciprocally 
related. Simultaneous to the reduction in cell respiration, the metabolic activity increased to 
equal extents, reaching levels up to 145%. This amplification levelled off until the end of 
treatment, with residual metabolic activity of 82% at 10 mM valproic acid. Neither cell 
respiration nor metabolic activity was reversible in the regeneration phase. The MTT assay 
indicated a statistically significant trend towards decreased HepG2 cell viability at 10 mM 
and 1.0 mM, showing 85% and 89% remaining viability, respectively (Table 6). 
 
 
Figure 35. Patterns of cytosensor signals upon stimulation of HepG2 cells with valproic acid. Cells were 
incubated with the indicated concentrations of valproic acid. Using the multiparametric cytosensor system, 
three physiological parameters were monitored on-line: cell impedance being an indicator of cell 
morphology/adhesion, cellular respiration based on oxygen consumption, and metabolic activity resulting in 
extracellular acidification. The grey areas indicate the initial stabilisation and final regeneration periods, 
which are carried out in the absence of a test compound. Control incubation in the absence of test 
compound was normalised to 100%. The patterns depict means of n ≥ 3 experiments. 
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5 DISCUSSION 
5.1 Real-time identification of P-glycoprotein substrates 
Drug interaction studies in pharmaceutical drug research are of great importance when 
assessing the potential of a drug to generate serious interaction effects with co-administered 
drugs. Because the amount of medications has increased significantly, especially in adults 
older than 55 (6), drug-drug interactions plays a pivotal role in the design of new drugs. 
The preliminary assessment of P-gp levels in L-MDR1 and parental LLC-PK1 cells indicates a 
high expression level of P-gp in L-MDR1 cells, and the absence of such in parental LLC-PK1 
cells (Figure 10). The level of P-gp in LLC-PK1 cells was possibly below the limit of detection, 
which was considered low enough to use the parental LLC-PK1 cells as a control cell line in 
the multiparametric cytosensor system. 
In the present project, a multiparametric, chip-based cytosensor system (Figure 7) was used 
for real-time identification of P-gp substrates in human P-gp overexpressing LLC-PK1 cells 
(L-MDR1). The results obtained with P-gp overexpressing L-MDR1 cells were compared with 
those of wild-type LLC-PK1 cells exhibiting only a marginal or no P-gp expression (161). Seven 
marketed drugs, known to be substrates or non-substrates of P-gp, were used as reference 
compounds for system validation: caffeine and propranolol are not substrates of P-gp, 
whereas verapamil, daunorubicin, fexofenadine, quinidine and loperamide are known 
substrates of the transporter. In contrast to previous studies in which pH microsensors were 
used for mechanistic studies on P-gp ATPase activation (162), the experiments here included 
measurements of cellular oxygen consumption and cell adhesion and were focused on 
efficient identification of P-gp substrates.  
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The multiparametric cytosensor assay was optimised with respect to maximal stimulation 
amplitudes to allow for sensitive, reliable recording of signals. Important assay parameters 
included the use of an assay medium with a low buffer capacity supplemented with 2.0% 
(v/v) foetal bovine serum albumin. Serum proteins reduce non-specific binding of test 
compounds to surfaces such as the plastic tubing of the microsensor instrument, and they 
enhance cellular viability in the assay system during incubation times of up to 24 h. Optimal 
cell densities were in a range of 0.75 to 1.5 x 105 attached cells per chip. The design of the 
actual incubation chamber (i.e. the volume of the 200 µm space between the surface of the 
sensor chip and the chamber lid) is of critical importance. In the experimental set-up, the 
effective volume of the incubation chamber was 5.7 µL (Figure 7). Such a minimal volume is 
needed to monitor the rate of accumulation of metabolic products and the depletion of 
oxygen in the assay medium. A further reduction of the incubation chamber volume led to 
cell hypoxia resulting in system instability and a high signal-to-noise ratio for the measured 
signal. During measurements, the flow of assay medium was periodically interrupted for two 
minutes. After each measurement period, the incubation chamber was flushed for another 
two minutes with assay medium before a new measuring cycle was initiated. Prolonged 
phases of reduced flow of assay medium should be avoided due to the detrimental effects 
on cell viability and overall system stability, resulted from oxygen depletion (hypoxia). 
Viability of cells was monitored continuously by measurement of cellular impedance. 
Deviations in the range of less than ± 20% from initial values over a run time of 1`500 min 
were considered acceptable and were attributed to cell proliferation or small morphological 
changes after compound treatment, i.e. shrinking or swelling. Experiments were 
discontinued as soon as a change in impedance in excess of these limits was recorded. 
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In a first set of experiments, activity of P-gp was monitored in the presence of verapamil (a 
P-gp substrate (40, 124)) and the negative control caffeine (125). Experiments were initiated 
as soon as a stable baseline metabolic rate was attained (100% threshold in Figure 12). 
Extracellular acidifications as well as respiration rates were identified as correlating with 
P-gp activation (Figure 12, phase 1 of the experiment). Selectivity of the observed P-gp 
stimulatory effects were demonstrated by inhibition of P-gp activity with elacridar 
(GF120918), a selective third-generation P-gp inhibitor (163, 164) (Figure 12, phase 3). 
Elacridar on its own does not stimulate P-gp ATPase activity, but has a slight inhibitory effect 
on overall metabolic activity of L-MDR1 cells (Figure 12, phase 2). At the end of the 
experiment (Figure 12), reference 0% signal-levels of the microsensor chip were determined 
by Triton X-100-mediated removal of attached cells.  
 
Observed acidification rates and respiration rates increased in the presence of increasing 
concentrations of up to 15 μM verapamil (Figure 13, black symbols) and followed 
Michaelis-Menten type kinetics. Stimulation of P-gp by verapamil showed saturation at high 
concentrations and was characterised by a KM value of 0.92 ± 0.12 μM (calculated based on 
extracellular acidification rates, mean ± SEM, n = 4) and 4.9 ± 2.7 μM (calculated based on 
respiration rates, mean ± SEM, n = 4). These values are in good agreement with a KM value of 
1.5 μM reported previously (165) for the stimulation of P-gp for verapamil at low substrate 
concentrations. It is important to note that, for the first time (to my knowledge) P-gp 
activation was monitored not only by extracellular acidification (165) but also by stimulation 
of cellular respiration. In the experimental setup, extracellular acidification rates deliver 
stronger and more reliable signals as compared to respiration rates: Vmax values for 
extracellular acidification rates (57.4 ± 1.6% as compared to 0% control, mean ± SEM, n = 4) 
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were twice as high as the corresponding Vmax values for respiration rates (25.4 ± 5.2% as 
compared to 0% control, mean ± SEM, n = 4). At substrate concentrations of 50 μM 
verapamil, a sudden drop in extracellular acidification rates as well as in respiration rates 
was observed and was attributed to substrate inhibition at high concentrations (162) of the 
test compound (Figure 13). However, none of the tested verapamil concentrations featured 
cell impedance deviations from 100% control values by more than ± 13%. In a separate set of 
control experiments (Figure 13, open symbols), P-gp-deficient LLC-PK1 cells were incubated 
in the presence of verapamil and did not show any stimulation effects in either extracellular 
acidification rates or respiration rates. Again, high concentrations of verapamil (50 μM) 
seemed to inhibit cellular metabolic activity, which is related to the limited capacity of the 
P-gp transporter and a resulting substrate inhibition as described previously (162). P-gp 
comprises two substrate-binding sites that can translocate slow diffusion compounds. In 
contrast, fast diffusion compounds (e.g. verapamil) can overrun the capacity of P-gp to 
translocate the compounds out of the cell and lead to an apparent substrate inhibition with 
decreasing kinetic parameters for higher concentrations. 
 
The question arises as to whether extracellular acidification rates or respiration rates should 
be used to monitor P-gp activation. Both parameters can be used to monitor cellular 
responses upon stimulation of cells using P-gp substrates and are therefore correlated with 
extracellular acidification rates is predominantly linked to glycolysis whereas respiration 
rates is indicative of mitochondrial respiration. In the experiments (Figure 12 and Figure 13), 
extracellular acidification was demonstrated to deliver a three-fold higher signal than oxygen 
consumption. In addition, baseline respiration rates changed over time during prolonged 
experimental periods. It is tempting to speculate that overall cellular viability and/or possibly 
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mitochondrial toxicity might be confounding factors that influence cellular respiration in an 
unpredictable way. In view of the reduced sensitivity as well as the uncertainty associated 
with the respiration rates parameter, it was decided to quantify P-gp stimulation based on 
extracellular acidification only, but to monitor respiration rates values as an additional 
control in parallel with identify cell-permeating compounds affecting mitochondrial 
respiration. 
 
The chip-based sensor system was also used to identify substrates of P-gp. Representative 
examples of marketed drugs are shown in Figure 14. Activation of P-gp was expressed as the 
ratio of acidification rates measured during and immediately before stimulation of L-MDR1 
cells (delta extracellular acidification rates). Propranolol, caffeine, quinidine, verapamil, and 
loperamide were used at a substrate concentration of 10 µM. The substrate concentrations 
of daunorubicin and fexofenadine had to be reduced to 1.0 µM to avoid cellular toxicity. 
Propranolol and caffeine, which do not interact with P-gp, were used as negative controls. 
All P-gp substrates were correctly identified and showed statistically significant differences 
(p < 0.05) in extracellular acidification rates as compared to the negative controls. Cellular 
impedance and thus cellular viability were not affected by the test compounds in the 
concentration range used. Absences of cellular toxicity or unspecific stimulatory effects were 
confirmed in a set of control experiments (Figure 15). None of the test compounds 
stimulated extracellular acidification rates using the P-gp-deficient LLC-PK1 cell line under 
the same experimental conditions. 
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5.2 Purinergic P2X7 receptor mediates metabolic changes upon ATP treatment 
This project investigated the effects of extracellular ATP on the metabolic activity of cells 
that overexpress the purinergic P2X7 receptor. I conclude that P2X7 receptors are mediators 
of these effects, based on the observation that high concentrations of ATP are necessary to 
induce these metabolic changes and on their inhibition by a selective P2X7 receptor 
antagonist.  
Hydrogen peroxide is a metabolic side product of cell respiration and can be used as a 
marker for changes in the metabolic activity of cells (126). I measured the hydrogen peroxide 
released in human mononuclear blood cells upon ATP treatment and found that ATP 
induced a concentration-dependent increase in H2O2 release with an EC50 value above 
500 µM (Figure 16A), confirming previous reports by Skaper et al. (166). In addition, the 
mass redistribution of HUVEC cells was assessed and showed EC50 values above 900 µM 
(Figure 17). Based on the similarity of EC50 values, I hypothesised the involvement of the 
P2X7 receptor in mediating the concentration-dependent increase in metabolic activity and 
morphological changes. To test my hypothesis, I used a specific P2X7 receptor antagonist 
and showed a strong concentration-dependent inhibition of the ATP-induced hydrogen 
peroxide release in human mononuclear blood cells (Figure 18). Furthermore, Bz-ATP, a 
specific agonist for P2X4- and P2X7 receptors (71), was used at a one-tenth concentration 
(400 µM) as compared to ATP (4`000 µM) and induced equal hydrogen peroxide release at 
these concentrations from human mononuclear blood cells (Figure 19); further indicating 
that the increased metabolic activity of the mononuclear blood cells were mediated by P2X7 
receptors.  
As a validation step, I initially confirmed the functionality of the P2X7 receptors in a 
recombinant HEK-hP2X7 cell line using the YoPro1 uptake assay and I confirmed the affinity 
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of the antagonist in blocking P2X7 receptors (Figure 24) with an IC50 of 11.2 nM. The 
experiments with the rodent cells and the YoPro1 uptake experiment were intended to 
compare and confirm the pharmacology of P2X7 receptors with the classical read-outs 
traditionally used for studying P2X7. 
I subsequently utilised these cells to further investigate the changes in metabolic activity by 
means of a cell-based, real-time monitoring sensor system, capable of simultaneously 
recording extracellular acidification as a marker for metabolic activity, oxygen consumption 
as a measure for cellular respiration, and impedance as a means to assess changes in cell 
morphology and adhesion. Pfeiffer et al. (128) previously described changes in cell 
morphology in the presence of P2X7 agonists in cells expressing P2X7 receptors, as P2X7 
receptors are co-localised with -actin, -actin, and the 2-integrin subunit, i.e. factors 
determining changes in the cytoskeleton components (167). These described morphological 
changes were detected and confirmed by the measurement of cellular impedance 
(Figure 20). In addition to this, HEK-hP2X7 cells exhibited concentration-dependent swelling 
upon treatment with Bz-ATP, possibly reflecting the osmotic influx of water into the cells due 
to pore dilatation. The estimated potency of Bz-ATP (Figure 21) in terms of cell morphology 
in this assay was calculated with an EC50 of 9.6 µM. The morphological changes detected in 
parental HEK293 cells were in the range of biologically acceptable deviations, emphasis the 
hypothesis that P2X7 is the mediator of the detected changes in P2X7 expressing cells.  
In addition, cellular respiration was maximally increased at 50 µM Bz-ATP to 23% as 
compared to parental cells. Treatment with 100 µM Bz-ATP led to a drop of 23% as 
compared to parental cells in cellular respiration, indicative for mitochondrial stress (168), 
whereas metabolic activity was amplified to 24% as compared to parental cells, providing 
evidence for a role of P2X7 in cellular metabolic activity. The resulting impairment in the 
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generation of ATP via oxidative phosphorylation was compensated to a certain extent by the 
enhancement of metabolic activity, monitored by an increase in extracellular acidification of 
up to 23% above the levels derived from control incubations with parental HEK293 cells. The 
reduction of cellular respiration was probably linked to the formation of reactive oxygen 
species (166) and activation of the apoptosis cascade (169).  
Using the multiparametric cytosensor system, I observed multiple readouts on cellular 
metabolism simultaneously, enabling a more complete picture to be generated of how ATP 
affects cellular metabolism through the P2X7 receptor. All effects on cell morphology, 
mitochondrial respiration, and metabolic activity, as induced by 50 µM Bz-ATP, were 
inhibited with potencies between 77% and 92% using 10 µM of the P2X7 receptor antagonist 
(Figure 22). Neither activation nor inhibitory effects were detected in parental HEK293 cells 
(Figure 22), suggesting that all effects were indeed mediated through the P2X7 receptor.  
I investigated how this link between P2X7 receptors and metabolic activity correlates with 
other functions of these ion channels. In patch-clamp experiments with mouse microglia BV2 
cells, which directly measure the flux of small, inorganic ions through these P2X7 channels, 
Bz-ATP showed distinct effects on the receptor activity (EC50 = 197 µM), and the selective 
P2X7 receptor antagonist had similar affinity (IC50 = 2.1 µM), indicating an involvement of 
the P2X7 receptor in mediating these agonist-induced effects (Figure 23).  
I also tested the impact of P2X7 on Ca2+ influx, and thus cell depolarisation (Figure 25). 
Primary rat cortical cells were used for these experiments, because P2X-mediated Ca2+ influx 
cannot be determined in HEK293 cells, due to the co-activation of endogenously expressed 
purinergic P2Y receptors (170). However, an experiment with exogenously generated P2X7 
activation led to an increased Ca2+ signal in the cells (171, 172) and was blocked by the P2X7 
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receptor antagonist (IC50 = 3.2 µM), with similar affinity as derived from patch-clamp 
experiments.  
From a comparison with other functions of P2X7 receptors, such as Ca2+ influx or 
depolarisation, it is not possible to deduce clear pathways from ATP-gated channel opening 
to the activation of cellular metabolism. Both small cations (Ca2+) influx and larger molecules 
entering the cell upon P2X7-related pore opening triggered further downstream effectors 
(i.e. interleukin-1 release, apoptosis, etc.) 
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5.3 Characterisation of drug-induced liver effects in HepG2 cells 
Identifying hepatotoxic effects of potential drug candidates that lead to drug-induced liver 
injury (DILI) in human remains a challenge. Standard preclinical animal models do not 
reliably predict human toxicity (animal concordance of 55%) (173).  
To improve predictability, specialised animal models can be combined with, for example, in 
silico, in vitro (endpoint assays) or toxicogenomic approaches (103). In this context, it was 
proposed that cytosensor systems be used to monitor reduction in metabolic rates as an 
indicator of cell death (174). Due to technical limitations, measurements were thereby 
limited to measuring cellular acidification rates. Only recently have novel, multiparametric 
sensor chips become available that can be used for the simultaneous determination of 
cellular impedance as a measure of cell morphology and adherence, oxygen consumption as 
a measure of mitochondrial respiration, and extracellular acidification as a measure of 
cellular metabolism, i.e. release of metabolic breakdown products such as lactate and 
carbonate resulting in a change in extracellular pH (110). In this project, high sensitivity and 
responsiveness of the multiparametric cytosensor system was achieved by combining an 
assay medium with low buffer capacity and a minimal inner volume of the perfusion 
chamber (Figure 7). The system therefore permitted real-time monitoring of physiological 
changes resulting from toxicological insult over a 24-hour period in human 
hepatocarcinoma-derived HepG2 cells. 
To validate the cytosensor approach, eight different reference drugs known to be 
hepatotoxic at certain concentrations (Table 5) were selected. They exhibit different 
hepatotoxic mechanisms and patterns of liver pathology. The drugs are structurally diverse, 
are used for different clinical indications, and the selection included the intrinsically 
cytotoxic drugs doxorubicin and methotrexate used to treat cancer. D-sorbitol, known to be 
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non-toxic and well tolerated even at high concentrations, was used as a negative control 
(160). Assay concentrations were comparable to clinically relevant plasma concentrations, 
covering a nanomolar to millimolar range. 
The test compounds have been reported to have different mechanisms of toxicity (Table 5). 
Cellular viability was measured by the MTT assay, which responded in a statistically 
significant manner to the antineoplastic drugs, acetaminophen, cyclosporine A and valproic 
acid (Table 6). Methotrexate and doxorubicin were used at clinical plasma concentrations as 
analysed in human cancer treatment. Clinical plasma concentrations of methotrexate and 
doxorubicin are measured at 1`150 µM (147) and at 1.9 µM (139), respectively. All other 
drugs investigated in the MTT viability assay reduced cell viability only at concentrations 
clearly above the clinically relevant human plasma concentrations. Interestingly, all analysed 
compounds known to cause DILI in humans also responded with very distinct and 
characteristic signal patterns in the multiparametric cytosensor assay (Figure 28 to 
Figure 35). All observed effects were rigidly concentration-dependent. This result was 
unexpected, because reactive metabolites (and not the parent compound alone) are often 
suspected sources of adverse effects (Table 5). Thus, in liver tissue, hepatotoxicity is 
frequently linked to accumulation of the parent drug in combination with its metabolites, 
initiating pathological effects, and/or an altered cellular defence mechanism, such as the 
depletion of glutathione (GSH), formation of ROS or the inhibition of metabolising enzymes. 
In the present study, the human hepatocarcinoma-derived HepG2 cell line was used. As 
opposed to primary human hepatocytes, HepG2 cells are characterised by a defined but low 
expression level of cytochrome P450 monooxygenases (113). In contrast, expression levels of 
most phase II enzymes seem to be normal (175, 176). The results suggest that phase II 
metabolic enzymes in combination with residual phase I metabolic enzyme (e.g. 
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cytochrome P450) activity may generate adequate levels of intracellular metabolites to 
trigger cytotoxic reactions. HepG2 cells therefore seem to be a convenient, stable, economic, 
and relatively easy to handle alternative to hepatocytes for cytosensor-based toxicological 
investigations. This view was supported by control experiments where amiodarone and 
acetaminophen were used to assess the phase I and phase II metabolising enzymes 
(Figure 26 and Figure 27).  
 
Analysis of the reference drugs in the multiparametric cytosensor system revealed distinct 
signal patterns that allowed for classification according to six distinct cytotoxic reaction 
types (Table 7, Figure 37).  
 
 
Figure 36. Classification of cytotoxic effects based on cytosensor signal patterns. Incubation of HepG2 cells 
with elevated concentrations of hepatotoxic drugs has an impact on cell morphology/adhesion (impedance, 
black line), metabolic activity (acidification, red line), and cellular respiration (oxygen consumption, green 
line). Cellular responses and cytotoxic effects can be classified according to six typical signal patterns 
(Table 7). Representative examples of experiments are shown in which treatment of HepG2 cells resulted in 
cytotoxicity and cell death (toxicological effects type 2 and 3) or cellular stress (effects of type 4 to 6). 
D-sorbitol served as a negative control (no cytotoxicity type l). Effects are considered reversible if baseline 
levels of signals are re-established after wash-out of drug (grey areas, absence of test compound). The 
patterns depict means of n ≥ 3 experiments. 
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Table 7. Classification of toxic effects based on multiparametric cytosensor signal patterns. Physiological 
parameters were monitored online in HepG2 cells and included metabolic activity (acidification), respiration 
(oxygen consumption) and cell morphology and adhesion (increased by swelling of cells or decreased by cell 
detachment or shrinking). Signals were stable over time (○), increasing in intensity (+) or decreasing  (－). 
Typical signal patterns of representative drugs are shown in Figure 36. 
 
Type Classification Endpoint Impedance Acidification Respiration Example 
1 No toxicity No effect ○ ○ ○ / +  D-sorbitol 
2 Necrosis-like Cell death － ○ / + + Valproic acid 
3 Apoptosis-like Cell death － ○ / + － Amiodarone 
4 Oxidative stress Cell stress ○ ○ / + － Acetaminophen 
5 Metabolic stress Cell stress ○ － + Methotrexate 
6 
Oxidative and 
metabolic stress 
Cell stress ○ － － Doxorubicin 
 
Type 1 is represented by D-sorbitol (Figure 36), a well tolerated and safe compound (160), as 
confirmed in the project. The slight increase in cell respiration of 20% at 5.0 mM during the 
24 h of the experiment was attributed to active compensation of the osmotic effect of 
D-sorbitol on cells.  
 
Type 2 signal patterns are represented by valproic acid (Figure 36). This compound is one of 
the most widely used antiepileptic drugs, with a black box warning for hepatoxicity. 
Oxidative stress, GSH depletion, as well as mitochondrial dysfunctions and necrosis have 
been associated with valproic acid treatment (159, 177-179). Recently, Ji et al. reported 
toxicological effects due to valproic acid and its reactive metabolites, suggesting an ability to 
damage liver cell plasma membranes and resulting in leakage of intracellular enzymes and 
finally cell death via necrotic or apoptotic pathways (158). These findings were confirmed in 
the cytosensor assay: an irreversible decrease of 50%, at 10 mM, of the impedance over 
time, which indicated cell death. This effect was preceded by a short and transient period of 
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water influx resulting in transient cell swelling (i.e. increased impedance), as described 
recently (180). A sudden drop in respiration was observed after the addition of valproic acid 
in the first 20 min of incubation, indicating reduced oxidative phosphorylation and hence 
reduced ATP generation. The reduced cell respiration was compensated by an increase in 
metabolic activity for a similar time range. The observed reduction of intracellular 
concentration of ATP led to strong oxidative and metabolic stress and caused an initiation of 
energy-independent necrotic-like pathways, which was detected in a previous study (181). 
Consequently, metabolic activity levelled off at 82% over the entire experiment. 
 
Amiodarone was used as a second drug with a black box warning for hepatoxicity and it is 
known to generate liver steatosis and hepatocellular death (119). In the multiparametric 
cytosensor system, the strong tendency of amiodarone to damage cells was confirmed (i.e. 
irreversible decrease in impedance) and was classified as type 3 (Figure 36), representing 
drugs causing apoptotic-like cell death. Amiodarone showed the most distinct 
concentration-dependent cytotoxic behaviour of all drugs analysed in this study. After 9 h of 
amiodarone treatment (15 µM and 30 µM), only 50% of the initial cells remained on the 
sensor chip. Higher concentrations of amiodarone showed almost complete inhibition of 
cellular respiration (15% of control), correlating with a continuous release of dying cells from 
the sensor chip. It is interesting to note that these concentrations of amiodarone can also be 
reached in human plasma (Table 5). Mitochondrial toxicity induced an amplification of 
metabolic activity as a compensatory but transient means of ATP regeneration. This 
compensatory mechanism failed after approx. 6 to 8 hours and amplified metabolic stress, 
as previously described (137) and demonstrated by the steep drop of the acidification curve 
down to 7%. Amiodarone showed no recovery of signals, thus identifying amiodarone as a 
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potent hazard to liver cells at elevated levels in tissue, without the possibility of 
regeneration. Furthermore, the observed effects support the previous findings of the 
production of reactive oxygen species, induced mitochondrial damage, and promoted 
apoptosis in HepG2 cells (182). It is still unclear whether amiodarone, its postulated reactive 
metabolite (desethylamiodarone), or both cause toxicity (133). However, the findings 
showed the significant potential of amiodarone to damage the liver, which was in good 
agreement with the black box warning of hepatoxicity on this drug. 
 
In contrast to drugs that induce cell death (i.e. type 2 and type 3 cytotoxicity), several drugs 
were identified that caused cellular stress only but no changes in cellular impedance. Three 
out of eight compounds in this study were identified as inducing oxidative stress in HepG2 
cells (type 4, acetaminophen, cyclosporine A, and isonidazide). Acetaminophen induces 
mitochondrial stress upon formation of its reactive metabolites as a consequence of 
depletion of GSH. Acetaminophen is widely used as an analgesic and antipyretic compound, 
and is classified as a non-steroidal anti-inflammatory drug. The first hours of the treatment 
phase showed slight and reversible shrinking of the cells, reflected by reduced impedance 
values of 70% to 80%, followed by an apparent regeneration period (Figure 36) during which 
the impedance was maintained at around 80%. This apparent regeneration is most likely 
linked to the disturbance of mitochondrial Ca2+ homeostasis (183), characterised by a 
phenotypic blebbing of the cell surface. Cellular respiration was intensely affected in a 
concentration-dependent manner and inhibited the respiration to 40% at 10 mM, indicating 
severe oxidative stress on the cell respiratory system, the formation of toxic benzoquinone 
metabolites, and the linked depletion of GSH, as previously described (131, 184). The intense 
impairment of respiration and the consequent deficit of oxidative phosphorylation results in 
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a lack of ATP generation. During such events, cells typically compensate for lack of energy 
generation by enhancing ATP generation via glycolysis, which is confirmed by the increase in 
metabolic activity to 130% at 10 mM. During the drug wash-out period, the signals of 
impedance and cell respiration almost recovered to initial baseline values prior to 
acetaminophen treatment. Wash-out of the drug reactivated the formation of ATP via 
oxidative respiration, leading to a decrease in metabolic activity, as the generation of ATP via 
glycolysis was no longer in demand. A study by Roe et al. (1993) confirmed the formation of 
the reactive metabolite (NAPQI) and phase 2 conjugation products in HepG2 cells, among 
others (e.g. benzoquinone) that were also responsible for adverse effects (113). 
Cyclosporine A showed similar effects (Figure 31) in all physiological parameters. This potent 
immunosuppressive agent prolongs survival of allergenic transplants by suppressing humoral 
immunity and, to a greater extent, cell-mediated immune reactions such as allograft 
rejection and delayed hypersensitivity. Unfortunately, cyclosporine A is associated with toxic 
effects to several organs, mainly the kidney, but also the liver, which is confirmed in my 
experiments. Oxidative stress was induced in HepG2 cells, particularly at concentrations 
equal to and above 30 µM followed by a regenerative phase and a slight compensatory 
amplification of the metabolic activity. It should be noted that the observed effects were 
apparent at concentrations that were 40 times higher than clinically relevant plasma 
concentrations of cyclosporine A and therefore of no direct clinical relevance. Additionally, 
cyclosporine A exemplified the limitations of the HepG2 cells, because the hepatoxicity of 
cyclosporine A is accompanied by the ability to inhibit hepatic bile-salt export transporters 
(e.g. ABCB11) (185). These pumps are responsible for the secretion of bile components into 
the bile canaliculi. A block of these bile-salt export pumps results in an intracellular 
accumulation of bile salts and thus cholestasis (119, 186). HepG2 cells are a common in vitro 
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model to analyse toxic effects on the liver (187). However, in previous studies, HepG2 cells 
showed impaired bile-salt transporter levels (188) and therefore HepG2 seems not to be the 
most appropriate model for studying such specific effects. An alternative to indicate 
toxicological effects linked with these efflux transporters would be the use of primary 
hepatocytes.  
 
Isoniazide, another example of a drug that induces oxidative stress, is associated with mild to 
severe liver toxicity in 2% of patients (189). Its metabolism is characterised by the formation 
of hydrazine (H2NNH2) and an additional toxic intermediate, isonicotinic acid. Hydrazine is a 
well-characterised hepatotoxin (190, 191). Hydrazine can be formed directly by 
amidohydrolase or indirectly via the isonicotinic acid pathway (N-acetyltranferase) to form 
acetylhydrazine and then hydrazine. Histopathological observations of isoniazide-induced 
liver toxicity reveal inflammatory processes and cell death (189). In the experiments 
(Figure 33), cellular respiration was affected in a concentration-dependent manner and was 
maximally reduced to 60%, indicative of previously described observations of oxidative 
stress to cells after isoniazide treatment (143, 144).  
 
Methotrexate is a compound that induces metabolic stress to cells (type 5, Figure 36). This 
drug is a folic acid antagonist used at high doses in cancer therapy. The intrinsic toxicity of 
methotrexate was evident in the MTT assay, showing reductions to 70% and 79% of cell 
viability at 50 µM and 200 µM, respectively. The mechanism of liver injury is poorly 
understood (152). The pathological pattern of methotrexate-induced liver injury varies from 
mild liver enzyme elevations to severe fibrosis and cirrhosis. Methotrexate enters the cell via 
a folate transporter and is retained within the cell as a polyglutamate (151). The drug inhibits 
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the enzymes required for the synthesis of purines and pyrimidines (192). It additionally 
blocks the conversion of homocysteine to methionine. High levels of homocysteine cause 
metabolic stress, with the above-described consequences, i.e. impaired metabolic activity 
(193, 194). Metabolic stress was clearly observed using the multiparametric sensor system, 
by a metabolic inhibition to a maximum of 60% of baseline values at 200 µM. The highest 
concentration (200 µM) investigated was six-fold below the detected clinical plasma 
concentrations in humans receiving methotrexate at high doses for anticancer therapy 
(1`150 µM, Table 5). Therefore methotrexate was a prime example of a drug that is 
intrinsically toxic, intensely inhibits metabolic activity and induced metabolic stress in HepG2 
cells, which was previously described (150). The amplified cellular respiration agreed well 
with the impaired glycolytic activity, which represents a compensatory mechanism to 
generate ATP. 
 
Doxorubicin indicates a combined pattern of oxidative and metabolic stress (type 6, 
Figure 36). Doxorubicin is an anthracycline derivate, commonly used in the treatment of a 
wide range of cancers, including hematological malignancies, many types of carcinomas, and 
soft tissue sarcomas. The MTT assay reflects the intrinsic cytotoxicity of the drug (54% 
viability at 25 µM), even at concentrations below the human plasma concentrations, which is 
1.9 µM (139). The MTT assay at 1.0 µM doxorubicin showed a statistical significant decrease 
in cell viability of 30% (Table 6) on HepG2 cells after 24 h treatment. During its metabolism, 
doxorubicin undergoes a one-electron reduction by different oxidoreductases to form a 
doxorubicin-semiquinone radical (195). The re-oxidation of the radical back to the parent 
drug leads to the formation of ROS and hydrogen peroxide (196). The reactive species might 
then cause oxidative stress, lipid peroxidation, damage to proteins and the mitochondrial 
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membrane, oxidation of mitochondrial DNA, as well as the activation of the redox-sensitive 
mitochondrial permeability transition pore (197). Consequently, the bioenergetics of the 
cells alters radically (198). I was able to monitor these effects in the cytosensor assay, in that 
cellular respiration was significantly inhibited (IC50 of < 5 µM), as a consequence of 
mitochondrial damage that inhibits cellular respiration. In addition, an inhibition of cellular 
metabolic activity was observed. These findings are in agreement with previous studies 
(197). Neither metabolic nor respiratory activities regenerated during the drug wash-out 
period, indicating irreversible impairment of cell viability, even at clinical relevant 
concentrations (Table 5). 
 
Using the multiparametric cytosensor system, I was able to monitor alterations in cellular 
metabolism, respiration and impedance in real-time. These changes were linked to the 
chemical-induced toxicological effects of the drug or its reactive metabolites. An assessment 
of reversibility of the effects was used to acquire additional insight into the underlying 
mechanisms of toxicity. In contrast to the well-established cellular viability (MTT) endpoint 
assay, the onset of toxic effects was monitored on-line, as opposed to the determination of a 
physiological endpoint. Based on these results, a Test-Flag-Risk Mitigation strategy 
(Figure 38) is being introduced; it can be used to extrapolate from an in vitro to an in vivo 
situation and to determine risk of cytotoxicity for a given test compound. I propose that 
signals from the cytosensor system should trigger an alert (flag) that will determine a further 
course of action and a follow-up strategy. Depending on concentrations used and 
reversibility of effects, animal experiments will be needed. Such studies can be combined 
with additional in vitro and/or in vivo experiments (e.g. enzyme induction or inhibition, drug 
transporter studies, etc.) to elucidate the mechanism of any adverse effect. Such a Test-Flag-
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Risk Mitigation strategy helps reduce the risk of hepatotoxicity and therefore leads to better 
management of risks associated with DILI. It remains to be elucidated whether this approach 
can be extended to other organ-specific cell lines that are used to evaluate organ specific 
toxicity (187). 
 
Figure 37. Test-Flag-Risk-Mitigation strategy based on findings in the cytosensor in vitro assay. Decisions to 
be taken during the drug discovery and development process will depend on the mechanism and extent of 
the observed cytotoxicity relative to the predicted therapeutic drug concentrations (i.e. classification as 
"low" or "high" drug concentrations). Potential risks uncovered in the multiparametric cytosensor test 
system will raise a flag and have to be addressed by confirmatory in vivo studies. 1Relative to the awaited 
plasma concentrations; 2increase the dose in animal models to elicit the adverse effects from the in vitro 
assay; 3probably detected also in animal toxicology models and the drug research discontinuation is already 
decided; 4further animal studies required for the clarification of the adverse effects and the in vitro-in vivo 
correlation; 5probably increase the dose in animal studies to classify the drug as `safe`.   
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6 CONCLUSION 
The basic mission of the pharmaceutical industries is to understand disease and to bring safe 
and effective new drugs to the market. For many reasons, the path to developing new drugs 
is fulfilled with hurdles and is comparable to the proverbial search for the needle in the 
haystack. The development of a new drug that fulfils all requirements is long (> 10 years) and 
very expensive (> 500 million dollars) and has a success rate of only 0.01%.  
Therefore, the pharmaceutical industry is looking for new assays to, for example comply 
with the safety requirements of the authorities, or more specifically to support drug 
discovery (e.g. discover new drug targets) and drug development (e.g. safety analysis). 
Considering this, the general idea of this PhD thesis was to use an in vitro technology that 
can monitor physiological parameters of cells and to develop novel assays that overcome 
obstacles in drug research.  
For the determination of the physiological alterations, I used a non-invasive, label-free 
multiparametric cytosensor system to monitor simultaneously extracellular acidification, 
cellular respiration, and cell morphology/adhesion.  
Drug-drug interactions and drug resistance are two of the most redoubtable detections in 
the development of a new drug, because they have a crucial influence on the 
pharmacodynamic and pharmacokinetic of a drug. A major role of these negative effects was 
imputed to the ABC-transporters and their famous member, P-gp. P-gp is found in many 
endothelial cells of the body, where it acts as a barrier to molecules, including drugs. In this 
case, efficient in vitro screening methods have been developed and used frequently in drug 
development. However, these assays are not necessarily reflecting the real in vivo situation 
and evince several limitations in the reliable identification of substrates of the P-gp 
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transporter. Utilising the properties of the P-gp transporter to hydrolyse ATP for the 
translocation of substrates, I was able to identify substrates for P-gp transporters by 
measuring the regeneration of the hydrolysed ATP in living cells expressing P-gp at high 
levels. The ATP regeneration process is linked to the excretion of acidifying metabolic 
breakdown products and increased oxygen consumption, and this was clearly observed using 
the multiparametric cytosensor system. Concentrations of compounds used in the 
experiments with the multiparametric cytosensor system showed great sensitivity, and this 
provides the opportunity to reduce concentrations of test compounds to more physiological 
relevant concentrations. Confirmatory experiments with cells lacking an expression of P-gp 
showed a clear absence of any effects detected with cells overexpressing P-gp. The effects 
were concentration-dependent and followed protein kinetic behaviour. The estimated 
protein kinetic parameters were in good agreement with previously published data. 
Summarising the results of the P-gp project it was possible to develop a novel, label-free and 
non-invasive technology to identify reliably P-gp substrates in living cells. The P-gp project 
serves as a proof-of-concept project and the extension of the validated application to other 
ATP-dependent transporters can be investigate. 
Another project was the characterisation of a potential new drug target, i.e. the purinergic 
P2X7 receptor, using the multiparametric cytosensor system. The effects of intracellular ATP 
are well described, but little is known about the effects of extracellular ATP, particular when 
the extracellular concentrations of ATP rise due to pathological circumstances. I analysed 
these effects and was able to link the detected physiological changes to the P2X7 receptor. 
The study identifies a leading role of the purinergic P2X7 receptor in mediating downstream 
signalling and thereby changes in cellular metabolism at non-physiologically high levels of 
extracellular ATP.  
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In summary, I discovered the role of P2X7 receptors in coupling extracellular ATP with yet to 
be elucidated intracellular metabolic pathways. Further experiments are necessary to 
investigate the specificity of the receptors involved in this link between extracellular ATP and 
metabolic activity and in what normal or pathological situations this coupling plays a role. 
Extracellular ATP has been shown to play a role in inflammation and apoptosis, and there are 
models of this relationship, between extracellular ATP and metabolic activity, that already 
exist, with both processes highly linked to metabolism. It is readily conceivable that P2X7 
receptor-mediated modulation of cellular metabolism contributes to some of the observed 
downstream effects, such as cytokine release, at least to some degree. 
In the third project, I used the multiparametric cytosensor system to identify adverse effects 
in liver cells upon exposure to drugs know to exhibit the potential to injure the liver. I used 
an established and characterised liver cell line (HepG2) and proved the possibility of using 
this cell line, despite its limitations in metabolic activity and expression of drug transporters.  
A panel of eight marketed drugs was used to develop a novel cytosensor-based in vitro 
toxicological assay. Reference drugs in my study were classified as either non-toxic 
(D-sorbitol), intrinsically toxic (antineoplastic drugs) or potentially toxic under conditions of 
exaggerated exposure resulting from, for example, intentional intoxication, drug-drug 
interactions or disease-induced physiological alterations. Drugs were tested using 
concentrations equal to, above, and below the clinically relevant plasma concentrations. 
Real-time monitoring of drug-induced physiological effects in HepG2 cells revealed 
characteristic signal patterns. Mechanistic insight into the action of these compounds was 
used to predict detrimental events such as cell stress, cell death, cytotoxicity, or DILI in 
humans. In addition, information was obtained on the reversibility of the observed effects. 
All identified alterations were rigidly concentration-dependent. My findings suggest that 
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cytosensor-based toxicological investigations may provide early indications of potential 
mechanisms of hepatotoxicity, which might be followed up by studies in experimental 
animal models. The early indications of potential mechanisms of hepatotoxicity, together 
with the Test-Flag-Risk Mitigation strategy, may therefore guide the design of specific follow-
up studies in experimental animals.  
Based on the capabilities of the multiparametric cytosensor system, it was possible to 
develop successful three new, supportive assays for different areas of the pharmaceutical 
research (i.e. preclinical, toxicology, and pharmacology) and the system therefore exceeded 
the expectations of the author of this PhD thesis. Based on the knowledge derived from the 
PhD thesis projects, it is possible to implement the multiparametric cytosensor system in 
laboratories for these specific disciplines and probably to extend its use to similar or 
different applications.  
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7 ABSTRACT 
The basic mission of the pharmaceutical industry is to understand disease and to bring safe 
and effective drugs to patients. Starting with the drug discovery process, for any particular 
disease a first step involves selecting a disease-specific target, then finding a suitable assay 
to determine the activity of molecules in relation to the selected target. This path is difficult 
and, lacking proper technology, is similar to the proverbial search for the needle in a 
haystack. However, once a molecule emerges as a successful candidate in the drug discovery 
process, it enters into drug development. The drug development process provides safety 
data prior to "first-in-man" trials. Drug discovery and development are extended, expensive, 
and inefficient processes with a success rate of only 0.01%. Placing these difficulties into 
perspective, it remains the desire of the pharmaceutical industry to develop novel, 
economical, reliable in vitro technologies to meet the above challenges.  
In this PhD thesis, a multiparametric cytosensor system was used for real-time identification 
of physiological parameters in living cells, and to meet the above-mentioned challenges in 
drug research. This technology allows us to simultaneously monitor extracellular 
acidification (pH changes), cellular respiration (oxygen consumption), and cellular 
morphology and adhesion (impedance measurements).  
All work done by a cell and all of the activities of life in general necessitate energy, 
commonly in the form of adenosine triphosphate (ATP). The regeneration of the consumed 
ATP leads to increased oxygen consumption and an excretion of acidifying side products 
(lactate and carbon dioxide), which can be monitored and used to deduce changes in 
physiological pathways.  
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The first project of this thesis explored the influence of the P-glycoprotein (ABCB1) 
transporter on drug-drug-interactions, drug resistance, as well as drug absorption and 
distribution, all of which are important factors to be considered during the development of 
new drugs. Thus, the early identification and the exclusion of compounds that show a high 
affinity to P-glycoprotein can help to select drug candidates. The aim of this first project was 
to use the multiparametric cytosensor system for the label-free identification of 
P-glycoprotein substrates in living cells by monitoring extracellular acidification and cellular 
respiration upon stimulation with substrates of P-glycoprotein. Using L-MDR1 cells, a human 
P-glycoprotein-expressing cell line, the influence of P-glycoprotein activity was determined 
for seven different compounds, demonstrating the applicability of the system for 
P-glycoprotein substrate identification. Effects were concentration dependent, as shown for 
the P-glycoprotein substrate verapamil, and were associated with cellular acidification and 
respiration. P-glycoprotein ATPase activation by verapamil was able to be described by a 
Michaelis-Menten type kinetics profile showing saturation at high substrate concentrations. 
Control experiments using a P-glycoprotein inhibitor indicated that the observed effects 
were related to P-glycoprotein ATPase activity. In contrast, wild-type LLC-PK1 cells that did 
not express P-glycoprotein were not responsive to stimulation with different P-glycoprotein 
substrates. Summarising these findings, the microsensor system used is a generic system 
suitable for the identification of P-glycoprotein substrates. In contrast to other biochemical 
P-glycoprotein assays, activation of the drug efflux pump can be monitored on-line and 
label-free in living cells in order to identify P-glycoprotein substrates and to study the 
molecular mechanisms of ATP-dependent active transport. 
The second project of this thesis explored the pharmacology of the purinergic P2X7 receptor 
and its influence on changes in metabolic activity after ATP treatment. The purinergic P2X7 
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receptor plays a prominent role in cell metabolism and possibly determines downstream 
effects based on its interactions with extracellular ATP. Adenosine triphosphate, a key agent 
in physiology, provides energy in numerous reactions and acts as a neurotransmitter. 
Extracellular ATP concentrations are known to rise under pathological conditions, thereby 
triggering immune system responses that lead to pro-inflammatory states and immune 
modulation, to the extent of initiating cell death. These adverse effects have been linked to 
the purinergic P2X7 receptor, which triggers downstream signalling when levels of 
extracellular ATP are high. The purinergic P2X7 receptor is also involved in modulating 
cellular responses that include membrane depolarisation, secondary messenger activation, 
Ca2+ influx, and activation of the mitogen-activated protein kinase pathway. Moreover, it 
features a unique ability to form a large, non-selective pore, allowing molecules up to 
900 Daltons to enter the cell, with potentially deleterious consequences. In addition, the 
P2X7 receptor purportedly regulates many metabolic processes inside the cell, while little is 
known of how extracellular ATP triggers these P2X7-mediated metabolic effects. In this 
study, the stimulatory effects of exogenously applied ATP on metabolic activity and the 
associated morphological changes in cells in relation to the P2X7 receptor were explored 
using the multiparametric cytosensor system for a deeper view inside the cell.  
Analysis of cell physiological parameters revealed that ATP-induced metabolic stimulation 
was detectable. Furthermore, based on signal patterns of the multiparametric cytosensor 
system, it was possible to detect ATP-induced oxidative stress to cells. Experiments with 
rodent brain cells that express P2X7 receptors demonstrated similar activation effects. 
Exploring and elucidating the evident relationship between the P2X7 receptor and 
extracellular ATP concentrations leads to the hypothesis that high levels of ATP reflect a 
pathological state and lead to an increase in metabolic activity in the cell. 
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The third project of this thesis explored liver toxicology and used the multiparametric 
cytosensor system to detect these adverse effects. The liver plays a pivotal role in the 
biotransformation and detoxification of drugs and is consequently vulnerable to potential 
injury as a consequence of significant drug exposure. Drug-induced liver injury (DILI) is of 
considerable concern in drug discovery and development, placing emphasis on the need for 
predictive in vitro technologies that identify potential hepatotoxic side effects of drugs. A 
label-free, real-time, multiparametric cytosensor system has therefore been established for 
in vitro assessment of drug-induced toxicity. The system is based on monitoring cellular 
respiration, metabolic activity, cell morphology, and adhesion of human hepatocarcinoma-
derived HepG2 cells. The read-out derived from the multiparametric cytosensor system has 
been optimised and permits sensitive, reliable, and simultaneous recording of cell 
physiological signals, such as metabolic activity, cellular respiration and morphological 
changes, and cell adhesion upon exposure to a drug. 
Analysis of eight prototypic reference drugs revealed distinct patterns of drug-induced 
physiological signals. Effects proved to be rigidly concentration-dependent. Based on signal 
patterns and reversibility of the observed effects, compounds were able to be classified as 
triggering mechanisms of oxidative or metabolic stress or as leading to cell death (necrosis-
like and apoptosis-like). A test-flag-risk mitigation strategy is proposed to address potential 
risks for drug-induced hepatotoxicity. 
Concluding all three projects, the general concept of monitoring the physiological 
parameters of cells with an in vitro technology to overcome obstacles in drug research has 
clearly been shown to be viable. It was possible to develop a successful, novel assay for 
reliable, real-time, label-free identification of potential drug-drug interactions based on the 
identification of P-glycoprotein transporter substrates. Furthermore, the pharmacology of 
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the purinergic P2X7 receptor after application of extracellular ATP was characterised and, 
finally and importantly, drug-induced liver effects were detected by on-line monitoring of 
liver HepG2 cells exposed to drugs. 
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